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ABSTRACT 
 
PROFILING PATIENTS WITH HEART FAILURE AND TESTING A 
MOTIVATIONAL INTERVIEWING INTERVENTION TO IMPROVE HEART 
FAILURE SELF-CARE  
  
Ruth M. Masterson Creber 
Barbara J. Riegel 
 
Background: Heart failure (HF) is the fastest growing cardiovascular syndrome in the 
United States and the most common reason for hospitalization of Medicare recipients. HF 
is prevalent, costly to society and complex to manage. The purpose of this body of work 
was to strengthen the evidence base for self-care by studying understudied aspects of HF 
self-care maintenance.  
Methods/Results: This body of work entails four discrete studies. The first study 
identified modifiable predictors of patients who are at risk of consuming a diet higher in 
sodium than recommended by the 2010 Heart Failure Society of America guidelines. The 
second study identified two unique patterns of sodium intake, “very high” (mean 4.5 
g/day) and “generally adherent” (mean 2.4 g/day). Predictors of the very high sodium 
intake group were being obese, having diabetes mellitus and less than 65 years old. The 
third study identified unique patterns of inflammation and myocardial stress in a sample 
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of patients with HF from the Heart Failure: A Controlled Trial Investigating Outcomes of 
Exercise TraiNing (HF-ACTION) clinical trial. Predictors of the worst biomarker pattern 
were identified and exercise was protective for being in the worst biomarker pattern. In 
response to these studies, the Motivational Interviewing Tailored Interventions for Heart 
Failure patients (MITI-HF) randomized controlled trial was designed and conducted to 
test the efficacy of a tailored motivational interviewing approach to improve self-care, 
physical HF symptoms and quality of life in patients with HF. Motivational interviewing 
was a successful approach for improving self-care maintenance, but there were no 
differences between groups for self-care management, self-care confidence, physical HF 
symptoms or quality of life.  
Conclusions: In the context of the rising prevalence of HF within an environment of 
increasing cost-conscious appropriation of healthcare resources, this body of work 
provides evidence for targeting self-care interventions to patients who are at highest risk 
of poor outcomes. It also provides evidence that motivational interviewing is a successful 
approach for improving self-care maintenance behaviors, specifically eating a lower 
sodium diet and exercising.   
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CHAPTER I: INTRODUCTION 
Background and significance 
 
Heart failure (HF) is a cardiovascular syndrome that affects more than 5.1 million 
Americans over the age of 20.1 Currently, HF is the fastest growing cardiovascular 
condition in the United States.2 Three primary risk factors of HF include age, 
hypertension and coronary heart disease. Hypertension and coronary heart disease 
currently affect approximately 77.9 and 15.4 million Americans over the age of 20 
respectively.1 Forecasts project that by 2030, 41.4% of all US adults will have 
hypertension.1 Increasing prevalence of coronary heart disease coincides with a decrease 
in mortality of coronary heart disease, (annual death rate declined 40.3% and the actual 
number of deaths declined 27.1% from 1999-2009).3 The decline in mortality from 
coronary heart disease results in a greater population at risk of developing HF, due to the 
fact that people are living longer with damaged myocardium. In addition, HF is a 
common endpoint for other prevalent cardiovascular and extra-cardiovascular diseases 
including: cardiac valve disorders, cardiomyopathy, diabetes mellitus, renal failure and 
obesity.4-7 The combined impact of these factors results in a projected 46% increase in 
HF prevalence from 2012 to 2030 resulting in more than 8 million people with HF.1  
Managing a single complex medical condition such as HF was estimated to cost 
$32 billion in the United States (U.S.) in 2012 and costs are estimated to increase 127% 
to 69.7 billion between 2012 and 2030.2 A large proportion of treatment costs are 
attributed to over one million annual hospitalizations in the U.S.,8,9 of which 90% are 
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potentially preventable.10 HF is the most common reason for the hospitalization of 
Medicare recipients.9 In total, heart disease accounted for almost 2 million discharges in 
2010 (among Medicare beneficiaries) with an average length of stay of 4.8 days and an 
average cost of $11,132 per hospitalization at discharge.11 Thirty-day readmission rates 
are reported to be as high as 27% 9 and more than one third are readmitted within 90 
days.9,10 Overall, HF hospitalization rate declined from 1998-2008, but at a lower rate for 
black men than for other demographic groups.1  
One avenue for cost savings is to reduce unnecessary hospitalizations. The costs 
incurred by Medicare for what may be preventable readmissions are estimated to be 
about $17 billion or 20% of Medicare’s hospital payments.10 Due to this high cost 
burden, the Centers for Medicare and Medicaid Services have taken a tough stance to 
reduce HF readmissions. As part of the Affordable Care Act, the Hospital Readmission 
Reduction Program has reduced payments to hospitals if patients with HF are admitted at 
the same or a different hospital within 30-days of a previous hospital admission.12  
Patients with HF frequently are readmitted to the hospital because they experience 
exacerbations in their symptoms caused by cardiac dysfunction, generally left or right 
ventricular hypertrophy, which cause neurohormonal and circulatory abnormalities, and 
manifest as symptoms such as fluid retention, shortness of breath and fatigue on 
exertion.13 HF is a complex syndrome to manage because clinical symptoms vary 
considerably between patients and during the course of the disease. Depending on the 
severity and degree of vigilance in management, recurrent bouts of acute exacerbations 
are common. If patients survive an acute exacerbation they are at high risk of 
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rehospitalization.14,15 To reduce the economic and social burden of HF and improve 
patient outcomes, better management strategies that incorporate optimized medical 
therapy in concert with effective self-care are critical.14-17  
Conceptual Model 
 
The concept of “self-care” in HF refers to the practices in which patients engage 
to maintain their own health and the decision-making process around managing signs or 
symptoms.18-20 In recent work by Riegel and colleagues, they provide evidence that self-
care decisions are guided by a naturalistic decision making process.21 Naturalistic 
decision making is defined as real-world decision making which takes into account 
multiple competing factors, limited time, uncertainty, high stakes, vague goals, unstable 
conditions and other unknowns.22 Self-care decision making is affected by situation 
awareness with mental simulation of a plausible course of action and evaluation of that 
outcome in addition to past experience, characteristics of the decision and personal 
goals.21 The naturalistic decision making process is particularly relevant in the context of 
HF because it is a chronic condition that requires constant decision-making around health 
practices and symptom management in order to maintain hemodynamic stability.20 Self-
care is measured most commonly in research with two instruments, the European Heart 
Failure Self-Care Behavior Scale23 and the Self-Care of Heart Failure Index.24 
Self-care entails two core components, choosing positive health practices (‘self-
care maintenance’) and making decisions around the management of symptoms signs and 
symptoms (‘self-care management’).18-20 The foundation of self-care is self-care 
maintenance, as illustrated in The Situation Specific Theory of Heart Failure Self-care19 
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(Figure 1.1). Self-care management builds on routine self-care maintenance practices 
starting with symptom monitoring and ending with critical decision-making and follow-
up. As such, symptom monitoring is a bridge between self-care maintenance and 
management. Recognizing symptoms is a necessary pre-cursor to being able to gauge 
symptom importance, implement treatment and evaluate the response. 
Figure 1.1: The Situation Specific Theory of Heart Failure Self Care  
 
 
Self-care maintenance 
Self-care maintenance involves performing positive health practices, such as 
medication adherence, consuming a low-sodium diet, staying physically active, 
monitoring daily weight and other symptoms, keeping medical appointments, avoiding 
tobacco and limiting alcohol consumption.20 Arguably the most critical daily self-care 
behavior is medication adherence—no other treatment is equally able to modify the 
physiological cascade associated with HF.20 Two of the most understudied aspects of 
self-care maintenance include eating a low sodium diet and doing routine exercise. In this 
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body of work, a particular focus will be given to these two self-care maintenance 
behaviors.  
 
Low-sodium diet 
Consuming a low sodium diet is one of the most frequently recommended self-
care behaviors; however, it is estimated that only 22-55% of HF patients adhere to a low-
sodium diet.25-27 The rationale for moderate sodium restriction is that in general, sodium 
promotes fluid retention, higher ventricular filling pressures and symptoms of congestion, 
all of which put patients with HF at higher risk for acute decompensation and 
hospitalization.25,28-31 The guidelines for HF are consistent in recommending a low-
sodium diet,13,32-36 though they differ in terms of their specificity—from general 
moderation32 to 2-3 g/day and further restriction for severe HF.13 All of the guidelines are 
based on expert opinion, or level C evidence, not clinical trial data.  
Exercise 
Patients with HF are encouraged to exercise because physiologically, regular 
exercise dilates coronary and peripheral skeletal vessels,37 stimulates angiogenesis,38 and 
causes reductions in peripheral hypoxia,39 local inflammation,40 and resting heart rate.41 
Results from smaller studies demonstrate that sustained exercise therapy improved 
myocardial contractility, diastolic filling, myocardial perfusion, and endothelial 
dysfunction.37,39,42-45 Despite this wide range of benefits, few patients with HF regularly 
engage in exercise.46,47 One of the reasons why few patients with HF routinely exercise is 
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that safety of exercise was not established until the results of the Heart Failure: A 
Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial were 
reported in 2008. Previously, health providers did not routinely recommend exercise.  
The purpose of HF-ACTION was to determine whether aerobic exercise could 
reduce all-cause mortality, all-cause hospitalization and improve quality of life. HF-
ACTION included 2,331 patients who were randomized to an exercise or control group 
for 30 months.48,49 Though there was no difference between the two study groups in all-
cause mortality or all-cause hospitalizations in the primary analysis, there was a 
difference in health status between the exercise training and control groups.50 The study 
reported in Chapter IV is based on a sub-sample of data from HF-ACTION.  
Self-care management 
Self-care management is a more complex process than self-care maintenance 
because it requires critical decision-making and follow-up action. Four steps to the self-
care management process have been specified. The first step entails recognizing early 
signs and symptoms. Though the recognition of symptoms may seem straightforward, it 
is not easy for many patients with HF to detect changes in their symptoms—including 
even large increases in body weight due to fluid retention.51 Many patients with HF have 
other co-morbid conditions so symptoms such as breathlessness or fatigue are often 
attributed to asthma, chronic obstructive pulmonary disease, lack of physical activity, 
over-exertion or aging.52 If symptoms are not routinely monitored and recorded then 
recognizing subtle changes that occur over time can be difficult. The second self-care 
management step entails deciding that a change in symptoms requires a response, 
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followed by taking action. Finally, patients need to be able to evaluate whether their 
response to the symptom was effective.20 
 
Factors affecting self-care 
There are multiple social, psychological, and physical factors that affect a 
patient’s ability to perform and maintain HF self-care. For instance, social support from 
family members, especially spouses, children and close friends, is instrumental in 
influencing adherence to prescribed medications.20,53-55 Depression is also associated with 
delays in seeking medical care56 and is one of the main psychological factors that affect 
self-care in HF.54 Depression is highly prevalent among both inpatients (50%) and 
outpatients (11-25%) with HF.57 People who are depressed are less likely to engage in 
health practices such as smoking cessation or regular exercise.58 Physically, general 
cognitive impairment is estimated to affect 25% of patients with HF, including 
impairment of executive function, memory, language, mental speed and attention.59,60 
Physiologically, cognitive impairment in HF can be caused by impaired cerebral vessel 
reactivity, microembolisms61 and chronic hypoperfusion.61,62As such, cognitive 
impairment adversely affects self-care.61,63,64 In addition, age and HF severity are 
associated with reduced cerebral blood flow due to abnormalities in the heart-brain 
vascular loop.62 HF is also associated with white-matter infarcts and reduced gray-matter 
volume,65 both of which impact memory, psychomotor speed and executive function,66 
which are critical for adequate self-care. Knowledge of how people with cognitive 
impairment perform self-care is limited by the fact that they are excluded from many 
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studies, due to ethical issues around informed consent, problems with follow-up, dropout 
and adherence to a protocol. Social support, depression and cognitive impairment are just 
three factors among many that influence a patient’s ability to maintain HF self-care.  
 
Self-care and Clinical Outcomes  
Self-care is considered an evidence-based recommendation for preventing health 
outcomes (ie: hospitalizations) and improving patient-oriented outcomes (ie: quality of 
life). Systematic literature reviews by McAlister and colleagues and Jovicic and 
colleagues report a decrease in HF hospitalization and all-cause re-hospitalization among 
patients who engage in self-care.67,68 A major limitation of this early work is that self-
care was not actually measured; it was assumed to be the mechanism by which event-risk 
was reduced. In the Heart Failure Adherence and Retention Trial (HART) trial (n=902), 
self-management counseling plus HF education was compared with HF education alone 
for the primary end point of death or HF hospitalization.69 There was no difference in the 
primary outcome between the two groups, suggesting that self-management counseling 
did not reduce death or HF hospitalization in patients with mild to moderate HF.70 Most 
recently, Dracup and colleagues reported the results of the Rural Education to Improve 
Outcomes in HF clinical trial. Once again, there were no differences in the clinical 
outcomes of hospitalization and cardiac death between patients randomized to the 
education intervention and control groups.71 The association between self-care and 
patient-reported measures of health status and quality of life is also unclear, primarily due 
to conceptual and methodological weaknesses in self-care intervention studies.72,73 In a 
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review of 21 interventions on the benefits of self-care on quality of life, some 
demonstrated improved quality of life in response to self-care interventions and others 
reported no effect.72 A positive association between HF self-care and health status was 
found when both self-care management and self-care confidence were high.74 While it is 
believed that self-care improves both clinical and patient-oriented outcomes, more 
research is needed to determine what dose and type of self-care interventions are needed 
to improve these outcomes. Evidence of improvement in health outcomes could impress 
patients with HF and clinicians of the critical role that self-care can have on both duration 
and quality of life.  
The relationship between self-care behaviors and specific biomarkers of 
inflammation and neurohormonal activation has been reported in a cross-sectional study 
of 168 symptomatic patients with HF.75 A one-point increase in the self-care management 
scale of the Self Care of HF Index was associated with a 12.7% reduction in levels of N-
terminal pro-B-type natriuretic peptide and soluble tumor necrosis factor receptor type 1, 
which are associated with higher risk of hospitalization and death.75 Lee and colleagues 
have proposed that oxidative stress may be reduced through better volume homeostasis, 
which decreases mechanical stress and ventricular wall stretch.20,75 That is, being attuned 
to early symptoms of congestion and responding promptly with effective self-care 
management techniques may promote fluid volume homeostasis.75-77 
In a review article on HF self-care, Riegel and colleagues support the 
development of personalized, or tailored, interventions to address barriers, improve self-
efficacy and focus on key self-care maintenance and management skills.20 In the context 
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of complex long-term conditions like HF, the rationale for using a tailored approach is 
that it may motivate individual patients and increase the likelihood that they will actively 
implement self-care maintenance or management behaviors.78 Tailoring is a form of 
individualization or personalization, which attempts to increase motivation by developing 
a customized plan that addresses relevant preferences and needs. Tailored approaches to 
cardiovascular disease prevention may involve the assessment of genetic variants, 
biomarkers and imaging modalities,2 as well as specific interventions and educational 
materials. Bennett and colleagues implemented tailored educational content to personal 
health beliefs and behaviors and found it improved self-care in patients with HF.79 
Tailored interventions are designed to take into consideration specific characteristics and 
desired outcomes of individuals using a combination of strategies and information based 
on individual assessment.80 Theoretically, tailoring may enhance the impact of a health 
message by altering attention and influencing how a message is processed by enhancing 
cognitive preconditions for effortful processing.81 Whether a tailored intervention will 
provide superior improvement in self-care and quality of life is addressed in this body of 
work.  
Purpose and specific aims  
 
 The primary purpose of this body of work was to strengthen the evidence base for 
self-care by studying specific HF self-care maintenance behaviors. The secondary 
purpose was to test the efficacy of a tailored motivational interviewing (MI) approach to 
improve self-care, quality of life, physical HF symptoms and clinical outcomes.  
  11 
The first aim was to identify patterns and predictors of high sodium intake. The 
hypothesis was that interventions that promote a low-sodium diet should be targeted to 
patients with HF who are most likely to consume high quantities of sodium. To address 
the first aim, two quantitative analyses were performed. As reported in Chapter II, 
predictors of higher than recommended sodium intake were identified using a mixed 
effect logistic analysis from a longitudinal dataset of 280 patients with HF. Secondly, as 
reported in Chapter III, two distinct patterns of sodium intake were identified using an 
alternative growth mixture modeling analysis. Conceptually, both of these studies address 
the self-care maintenance skill of maintaining a low-sodium diet.  
Table 1.1 Aim 1: Patterns and predictors of high sodium intake 
Aim Title of paper for how aim was 
addressed 
1) Identify predictors of high sodium intake. 
 
Hypothesis: Identifying predictors of high sodium 
intake informs who should be targeted with low-
sodium diet interventions. 
Chapter II: Identifying predictors of 
higher than recommended sodium intake 
in HF patients using a mixed effect 
logistic analysis of longitudinal data 
 Chapter III: Using growth mixture 
modeling to identify subgroups of 
sodium adherence in adults with HF 
 
2) Identify distinct biomarker patterns and 
identify predictors of the worst biomarker pattern. 
Chapter IV: Identifying biomarker 
patterns and predictors of inflammation 
and myocardial stress 
Hypothesis: Common and distinct patterns of 
biomarkers of inflammation and myocardial stress 
can be identified. Predictors of these patterns can 
also be identified and subsequently used to target 
high-risk patients.  
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3) Design and implement Motivational 
Interviewing Tailored Intervention (MITI-HF) to 
improve HF self-care.  
 
Hypothesis: Participants in the motivational 
interviewing group will have higher self-care 
outcome scores, quality of life and physical 
symptoms burden compared to the usual care 
group.  
Chapter V: Motivational interviewing 
tailored interventions for heart failure 
(MITI-HF): design and methods 
 
Chapter VI: Motivational interviewing 
tailored interventions for heart failure 
(MITI-HF): self-care, physical HF 
symptoms and quality of life  
 
 
The second aim was to identify common and distinct patterns of change in serum 
biomarkers of inflammation and myocardial stress and quantify the influence of exercise 
therapy on patterns of change in a community-based sample of patients with HF. 
Currently, little is known about which a priori factors predict biologic patterns 
characterized by inflammation and myocardial stress in patients with HF. As reported in 
Chapter III, three distinct patterns of inflammation and myocardial stress were identified 
and predictors of the worst biomarker pattern are reported. Conceptually, this study 
supports the self-care maintenance behavior of exercise as a mechanism for slowing the 
progression of HF.  
The third aim, reported in Chapters V and VI, was to test the efficacy of MI to 
improve self-care behaviors, physical HF symptoms and quality of life in patients 
recently discharged from a HF hospitalization.  Differences between the study groups 
were tested and reported for statistical and clinical improvement from baseline to 90-days 
in self-care maintenance, self-care management, self-care confidence, physical HF 
symptoms and quality of life.  This study supports using a tailored motivational 
interviewing approach to improve heart failure self-care maintenance.  
  13 
Summary 
 
 This dissertation explores multiple bio-behavioral methods for profiling patients 
with HF who are most vulnerable to poor self-care, physiologic and clinical outcomes. 
This work specifically addresses characteristics of patients who are at higher risk of 
consuming a high-sodium diet and predictors of worse patterns of inflammation and 
myocardial stress, both of which can be used to target interventions to the most 
vulnerable patients with HF. This work also tests whether a tailored motivational 
interviewing intervention is able to improve self-care behaviors, physical HF symptoms 
and quality of life and in a pilot randomized controlled trial.  Finally, this body of work 
concludes with overall themes and recommendations for future research and clinical 
practice.  
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Abstract 
 
Background: A low-sodium diet is a core component of heart failure self-care, but 
patients have difficulty following the diet.  
Aim: The aim of this study was to identify predictors of higher than recommended 
sodium excretion among patients with heart failure. 
Methods: The World Health Organization Five Dimensions of Adherence model was 
used to guide analysis of existing data collected from a prospective, longitudinal study of 
280 community-dwelling adults with previously or currently symptomatic heart failure. 
Sodium excretion was measured objectively using 24-hour urine sodium measured at 
three time points over six months. A mixed effect logistic model identified predictors of 
higher than recommended sodium excretion.  
Results: The adjusted odds of higher sodium excretion were 2.90, (95% confidence 
interval (CI): 1.15-4.25, p<0.001) for patients who were obese; 2.80 (95% CI: 1.33-5.89, 
p=0.007) for patients with diabetes; and 2.22 (95% CI: 1.09-4.53, p=0.028) for patients 
who were cognitively intact. 
Conclusion: Three factors were associated with excess sodium excretion, and two, 
obesity and diabetes, are modifiable by changing dietary food patterns.  
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Introduction 
 
Heart failure is a major public health concern because it is associated with high 
morbidity, mortality and cost. Self-care is recognized as a means of improving these 
outcomes.1 Consuming a low-sodium diet is one of the most frequently recommended 
self-care behaviors; 2-5 however, it is estimated that only 22-55% of patients with heart 
failure are adherent to a low-sodium diet.6-8 The rationale for not consuming excessive 
sodium is that it can lead to fluid retention, higher ventricular filling pressures and 
symptoms of congestion9—all of which put patients with heart failure at risk for acute 
decompensation and hospitalization.10, 11 
The general recommendation for all adults in the United States is to consume less 
than 2,300 milligrams (mg) of sodium a day; however, the average American consumes 
approximately 3,400 mg of sodium per day.12 Sodium is one of the primary cations in 
extracellular fluid. By influencing the shifting of water between body compartments, it 
plays an important role in maintaining body fluid tonicity,13 blood volume and pressure. 
The Heart Failure Society of America (HFSA) guidelines recommend that patients with 
symptoms of heart failure restrict daily sodium intake to 2,000-3,000 mg/day. 6 The most 
recent 2013 American Heart Association (AHA) Guideline for the Management of Heart 
Failure recommends sodium restriction (< 3000 mg/day) for patients with stage C and D 
heart failure.14 
Patients with heart failure face a number of barriers to effectively quantifying 
sodium intake and maintaining a low-sodium diet. A major barrier is that many patients 
do not find low sodium foods palatable and consequently never adjust to the taste of low 
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sodium foods and change their eating habits.15 A lack of knowledge about how to identify 
high sodium foods, even when labeled, is also a barrier for patients.15-18 Few restaurants 
offer low-sodium options, which decreases dining out opportunities for socialization with 
friends.15-17 Overall, there are multiple barriers that can impede patients with heart failure 
from consistently following a low-sodium diet.  
The aim of this study was to identify socio-demographic and clinical 
characteristics that predict higher than HFSA recommended sodium intake, estimated by 
urinary sodium excretion, using longitudinal data of patients with heart failure. For the 
purposes of this study, we assumed that sodium excretion was a reflection of sodium 
consumption. The World Health Organization (WHO) Five Dimensions of Adherence 
model was used to identify factors potentially associated with poor dietary adherence.19 
This holistic model acknowledges the multi-dimensionality of adherence including social 
and economic conditions, the health care system, as well as condition-, therapy- and 
patient-related factors.19 Previously, this model has been used to guide the assessment of 
medication adherence in patients with heart failure.20 
Methods 
 
Study population 
This study was a secondary analysis of data collected in an observational 
prospective cohort study of 280 community-dwelling adults with previously or currently 
symptomatic heart failure who were followed over a six-month time period. This study 
was in compliance with the Declaration of Helsinki.21 Institutional Review Board 
approval was obtained from all three sites and all participants gave written informed 
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consent. The parent study was conducted to investigate the relationship between 
excessive daytime sleepiness and heart failure self-care. The detailed methodology of this 
study has been reported elsewhere. 22 In brief, this was a prospective cohort study with 
patients assigned to one of four cohorts based on excessive daytime sleepiness and 
cognitive decline. Multiple heart failure self-care behaviors were measured including 
eating a low sodium diet, which was assessed with 24-hour urine sodium specimens at 
three time-points (enrollment, 3- and 6-months). Patients with heart failure were 
prospectively enrolled from three outpatient settings, two in Pennsylvania and one in 
Delaware, between 2007 and 2010. The basic eligibility criteria for participation 
included: (1) chronic heart failure with prior or current symptoms, (2) ability to read and 
speak English, and (3) sufficiently able to complete questionnaires and study procedures 
(i.e. adequate cognition, English fluency, ability to read). Patients were ineligible to 
participate in the study if they had dementia, as measured by the Telephone Interview for 
Cognitive Status23 along with other criteria specified in the parent study. 22 Most 
participants in this study were followed in specialty heart failure clinics and were on 
standard medical therapy.  The usual care provided by heart failure specialty clinics was 
not augmented in this observational study.  
Variables and Measures  
Clinical information (e.g., etiology and type of heart failure, left ventricular 
ejection fraction (LVEF), and comorbid illnesses) was abstracted from the medical record 
by a registered nurse at each of the three enrollment sites. These nurses were familiar 
with the unique electronic medical record systems in their own setting. Each nurse 
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received extensive training to assure consistency of data collection. The principal 
investigator assured the fidelity of the data collection protocol at each site and was 
available for questions throughout the study period.  
Comorbidities (including diabetes) were scored with the Charlson Comorbidity 
Index, a commonly used measure,24 directly from the medical record. In this sample, all 
patients had a score of at least one because they all had heart failure. Validity was 
demonstrated by the instrument authors when comorbidity scores (categorized as low, 
medium, and high) predicted risk of ten-year mortality, complications, health care 
resource use, length-of-hospital-stay, discharge disposition and cost.24-27 
New York Heart Association (NYHA) functional class was scored Class I-IV by a 
single board certified cardiologist using data obtained from a standardized interview.28 
Body mass index (BMI) was calculated based on patients weight at the baseline visit and 
self-reported height. Detailed information on participants’ medications, with doses, was 
collected at each data collection period. Sociodemographic characteristics were self-
reported.  
Cognition was measured with a battery of neuropsychological tests administered 
in person by trained research assistants. The number of tests on which participants scored 
below their age-based norm was used as an indicator of cognitive status. Any participant 
who scored more than 1.5 standard deviations beyond the range of normal on at least two 
of the paper-and-pencil tests was considered to have mild cognitive decline. For analysis, 
the cognition variable was dichotomized to indicate those with or without cognitive 
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impairment. The details of the neurocognitive battery and methodology for categorizing 
cognitive status are reported in detail in the parent study.22 
In this study, dietary sodium intake was approximated using urine sodium 
excretion. Sodium is under tight homeostatic control and is only lost from the body as 
sweat (20-80 mmol/day), stool (5-10 mmol/day) or urine (1-500 mmol/day).29 Patients 
with heart failure do not typically engage in strenuous physical activity; therefore do not 
lose sodium from heavy perspiration.  Variations in sodium excretion are primarily due to 
variations in recent sodium intake.30 In this study, we made the assumption that the 24-
hour urinary sodium excretion samples reflected dietary sodium intake across the study 
period, consistent with previous studies.10, 31, 32 The 24-hour urine collection method has 
been validated by urine recovery of oral doses of para-amino benzoic acid 33-35 and the 
collection procedures followed in the parent study were consistent with recommendations 
for collection by the Institute of Medicine.36 
Based on criteria set forth by the 2010 HFSA practice guidelines and published 
papers, urine sodium in mmoles was converted to mg (mg= mmole*22.99).5, 10 The urine 
sodium binary outcome in this study was created using 3,000 mg/day 24-hour urine 
sodium cut point for patients in NYHA Class I/II and a 2,000 mg/day 24-hour cut point 
for patients in NYHA Class III/IV. Expected dietary sodium categories were compared 
between participants whose dietary sodium excretion was within recommended levels 
versus those in higher than recommended levels. 
Procedures 
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Data were collected at baseline, three, and six months by research assistants 
during home visits. Training for urine specimen collection was provided for the patient 
and family member, if available, at the baseline data collection interval. Prior to each 
subsequent urine collection, patients were telephoned to remind them and reinforce 
training for the procedure. Patients were given urine containers, collection devices, verbal 
and written instructions (with pictures) specifying when they should start and finish 
collecting the urine specimen. Participants were instructed to start the collection at 0800, 
discard that specimen, and collect the final specimen at 0800 on the following day. Prior 
to the patient collecting each urine specimen, the research assistant inquired about 
changes in the medication regimen. If the participant had experienced a recent medication 
change the collection was delayed for three days starting from the date the medication 
was changed. Participants recorded when their urine sodium collection started and 
finished. A courier picked up the specimens from the participant’s homes after the 24-
hour sample was completed.  
The central laboratory at the Hospital of the University of Pennsylvania analyzed 
the urine samples to determine the amount of sodium in each specimen using the ion-
selective electrode method (Beckman LX® 20 Chemistry Analyzer, Beckman Coulter, 
Inc., Fullerton, CA).  
Statistical Analysis 
Descriptive statistics were used to calculate frequencies with percentages and 
means with standard deviations for the total sample, urine sodium in grams per day, and 
sodium consumption. Chi-square and Kruskal-Wallis tests were used to compare baseline 
  29 
characteristics of binary, categorical and ordinal variables between groups. For the 
purposes of between group comparisons, the doses for patients on loop diuretics (n =183) 
were converted to furosemide equivalents using the following formula: furosemide 80 mg 
= torsemide 40 mg = bumetanide 2 mg.37 The other participants on diuretics (n = 8) were 
prescribed hydrochlorothiazide and compared separately. This method has been used in 
other studies.10 
Over the three points of data collection, data on the urine sodium excretion were 
missing overall in 23% of the participants (193/840 samples), 19% at baseline, 29% at 3-
months and 23% at 6-months. Multiple imputations were performed for urinary sodium 
excretion and body mass index (BMI) data to account for missing time-varying 
covariates.38-40 Multiple imputation is a principled, likelihood based method using 
statistical modeling to impute data using the method of chained equations.41 In short, this 
method creates ten copies of the data, as recommended by Rubin.40 The multiple 
imputations were based on baseline age, gender, etiology of heart failure, cognitive status 
and LVEF and complete data for time-varying covariates, including NYHA class, BMI 
and urine sodium excretion. Each dataset was then analyzed separately. 42 Estimates of 
the parameters of interest were averaged across all the datasets to give a single, final 
estimate. 42, 43 After imputation, data were checked to confirm reasonable values. 
Standard errors and 95% confidence intervals were estimated by calculating within and 
between components of variance using the method of Rubin.40 
To determine predictors of higher than recommended sodium intake, a mixed 
effect logistic model with a random intercept was tested for each patient. Adjusted odds 
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ratios, 95% confidence intervals and p-values are presented for statistically significant 
predictors of higher than recommended sodium intake fit on the imputed data.44 The 
selection of model covariates was based on four of the five dimensions of adherence from 
the WHO conceptual model: condition, therapy, patient-related factors and social and 
economic conditions as well as statistical association with the outcome variable, urine 
sodium excretion.  The final twelve covariates included in the multivariable regression 
models are presented in Table 2.1.45  
Table 2.1: World Health Organization five dimensions of adherence model 
Dimension of adherence Variables used in this study 
     Social/economic factors race, income, highest level of education 
     Therapy-related factors diuretic (loop or thiazide) 
     Patient-related factors gender, age, body mass index, cognitive status 
     Condition-related factors heart failure type (diastolic or systolic), diabetes, 
hypertension, etiology (ischemic or non-ischemic) 
     Health-system factors Not available in this study 
 
Two sensitivity analyses were conducted. First, mixed effect logistic estimates 
were compared between the complete case and imputed data models. Estimates based on 
imputed data were more conservative in terms of effect sizes and had narrower 
confidence intervals. This was expected because confidence intervals and model variance 
depend on the amount of missing data, sample size and number of imputed datasets.41, 46 
Second, estimates from the mixed effects logistic models were confirmed with 
generalized estimating equations models with robust standard errors. Data are not shown 
for these two sensitivity analyses because there were no significant differences between 
the models. All data analyses were performed using Stata v. 11.2.47 
Results 
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  This sample of patients with heart failure had a mean age of 62 years (standard 
deviation (SD): 12), was predominantly male (64%), functionally compromised (77% in 
NYHA class III or IV) with a mean left ventricular ejection fraction of 35 (SD: 17). Over 
one-third of the sample had diabetes. Among participants with diabetes 60% were also 
obese. Over two thirds of the sample had hypertension, and about 20% had chronic 
obstructive pulmonary disease. Sample demographic and clinical characteristics are 
shown in Table 2.2. The urine sodium levels were relatively normally distributed so 
mean and standard errors are presented. The majority of the sample was prescribed 
furosemide or an equivalent loop diuretic.  
Table 2.2 Demographic, social and clinical characteristics of patients and 24-   
hour urine sodium urine samples: overall and by higher and lower sodium     
excretion levels at baseline (N=280) 
Variables Total  % Mean UrNa 
grams/day 
(SE) 
Na+ guidelines 
Within  or  
Higher 
p-value 
Age        
   <65 years 165 41 3.08 (0.03) 48 63 0.022 
   >=65 years 115 59 2.61 (0.03) 52 37  
Gender 
    Male 
    Female 
 
180 
 
64 
 
3.23 (0.24) 
 
61 
 
66 
 
0.425 
100 36 2.81 (0.03) 39 34  
Race 
    Black/Other 
    White 
 
105 
 
38 
 
2.95 (0.02) 
 
33 
 
37 
 
0.597 
175 62 3.30 (0.04) 67 63  
Income       
    More than needed 98 35 2.75 (0.03) 38 33 0.269 
    Enough for needs 137 49 3.21 (0.03) 51 48  
    Less than needed 45 16 3.35 (0.05) 11 19  
NYHA functional class          
    Class I+II 
    Class III 
    Class IV 
 66 
 
23 
 
3.03 (0.04) 
 
 33 
 
17 
 
0.009 
164 59 3.02 (0.03) 49 68  
50 18 3.28 (0.06) 18 15  
Diuretic use*       
    Furosemide equ.   
    (mg/day) n=183 
183  3.07 (0.15) 72 69 0.703 
<= 40 mg/day  91 50 2.97 (0.14)    
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>40 and <=120 
mg/day  
63 34 3.33 (0.27)    
>120 mg/day  29 16 3.01 (0.27)    
    Hydrochlorothiazide    
    (mg/day) 
  8 3 3.30 (0.53) 1 3 0.400 
HF etiology  (n=279) †       
    Ischemic HF 102 36 3.11 (0.03) 35 38 0.625 
    Non-ischemic HF 177 64 3.05 (0.03) 66 61  
BMI (n=279) †       
   Normal (18-24) 74 26 2.39 (0.03) 38 18 0.001 
   Overweight (25-29) 73 26 2.86 (0.05) 27 27  
   Obese (30+) 133 48 3.53 (0.02) 35 55  
Highest level of 
education 
      
    Less than high 
school 
27 10 2.65 (0.07) 11 7 0.271 
    High school 
graduate 
102 36 3.05 (0.03) 39 35  
    More than high 
school 
151 54 3.12 (0.03) 50 58  
Type of heart failure       
   Systolic 194 69 3.00 (0.02) 76 69 0.475 
   Diastolic or mixed 86 31 3.19 (0.05) 24 31  
Charlson Co-morbidity       
  Low 149 53 2.96 (0.04) 56 50 0.268 
  Moderate 101 36 3.13 (0.06) 37 35  
  High 30 11 3.26 (0.09) 7 15  
Diabetes       
   Yes 107 38 3.57 (0.05) 23 47 0.001 
   No 173 62 2.72 (0.04) 77 53  
Hypertension       
  Yes 181 65 3.06 (0.02) 65 63 0.729 
   No 99 35 3.07 (0.03) 35 37  
COPD       
  Yes 222 79 2.53 (0.06) 73 81 0.129 
  No 58 21 3.20 (0.03) 27 19  
Cognition      0.004 
  Cognitively impaired 107 39 2.90 (0.02) 47 28  
  Not cognitively    
  impaired 
165 61 3.14 (0.03) 53 72  
*Diuretic use: This only includes information on patients who were on diuretic medications. The 
proportions are only for those prescribed furosemide (n=183), not the entire population sample. †Sample 
size for variables with missing values. Abbreviations: SE=standard error, Na+=sodium, UrNa=urine 
sodium, NYHA=New York Heart Association, COPD=chronic obstructive pulmonary disorder 
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The median and interquartile range values for urine sodium excretion on the 
complete cases at all three time points were 2,770 mg (1,750 – 3,950 mg) at baseline, 
2,630 mg (1,690 – 4,000 mg) at 3-months and 2,780 mg (1,900 – 3,790 mg) at 12-
months. There was no trend in sodium excretion across time that would suggest that 
participants modified their diets in anticipation of these measurements. We found no 
difference in the pattern of observed values for participants with missing data and those 
with complete observations. 
Table 2.3 Factors associated with higher sodium excretion (n=280) 
Variables Adjusted OR 95% CI p-value 
Cognition    
    Cognitively impaired 1.00 Reference __ 
    Cognitively intact 2.22 1.09   4.53 0.028 
Body mass index    
    Normal (18-24) 1.00 Reference __ 
    Overweight (25-29) 1.79 0.75    4.25 0.187 
    Obese (30+) 2.90 1.15    4.25 <0.001 
Diabetes    
   No 1.00 Reference __ 
   Yes 2.80 1.33   5.89 0.007 
Gender    
    Female 1.00 Reference __ 
    Male 1.16 0.54    2.51 0.703 
Age     
    >=65 years 1.00 Reference __ 
    <65 years 1.95 0.97    3.90 0.059 
Hypertension 0.51 0.25   1.04 0.068 
Income  1.11 0.67    1.84 0.696 
Diuretic use  1.05 0.48    2.33 0.897 
Heart failure etiology  0.72 0.31    1.67 0.438 
Type of heart failure  1.24 0.78    1.98 0.351 
Education 1.14 0.67    1.96 0.607 
Race 1.17 0.57    2.42 0.663 
Abbreviations: OR: odds ratio, CI: confidence interval  
 
In the final model identifying patient characteristics associated with higher than 
recommended sodium intake (Table 2.3), patients with heart failure who were obese 
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(BMI>30) had nearly three times higher adjusted odds of consuming more than 
recommended sodium intake compared to patients with a normal body weight (BMI<25). 
The adjusted odds of sodium intake above recommended level were over two times 
higher in patients who were cognitively intact compared to patients with some cognitive 
impairment. Patients with heart failure and diabetes had almost three times the adjusted 
odds of consuming more than the recommended sodium intake. 
Discussion 
 
The purpose of the study was to identify characteristics of patients with heart 
failure who had higher than recommended 24-hour urine sodium excretion. In this study, 
we used 24-hour sodium excretion as an estimate of dietary sodium intake, or adherence 
to sodium guidelines. Considering possible predictors drawn from the WHO adherence 
model, the three most important predictors of higher sodium excretion were patient- and 
condition-related factors. Patients with heart failure who were obese or had diabetes and 
those who were cognitively intact were more likely to excrete higher amounts of sodium. 
The association between higher sodium and obesity is most likely explained by 
both direct and indirect effects.32, 48 One explanation for the relationship between obesity 
and higher sodium consumption is that high-calorie foods often contain high sodium.49 
Increased dietary sodium intake is directly correlated with increased calorie 
consumption.31, 50 According to the Salted Food Addictive Hypothesis, salted foods act in 
the brain like an opiate agonist, producing a hedonistic reward, which becomes associated 
with foods being judged as “delicious” or “flavorful.” 48 Withdrawal of salty foods acts 
like an opiate receptor withdrawal and causes perceived “cravings” for salted foods.48 
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Over time, daily consumption of salted foods can produce an addiction, which escalates 
and can stimulate overeating.51  
The association between high sodium intake and obesity has also been found in 
rat animal models52 and has a physiological explanation: chronic salt overload induces 
adipocyte hypertrophy, which enhances insulin sensitivity for glucose uptake and insulin-
induced glucose metabolism.52 Song and colleagues report a direct effect between sodium 
intake and risk of being overweight in humans, after adjusting for energy, water and soda 
consumption;32 however their study sample did not include patients with heart failure, 
hypertension or diabetes. The relationship between obesity and sodium consumption is 
consistent with results of our previous study in which we found that patients with heart 
failure who were overweight had a four-fold increased odds of consuming more than 
3,000 mg of sodium per day.53  
Other lifestyle factors may help explain the relationship between obesity and 
sodium consumption. Processed and packaged foods are naturally high in sodium because 
sodium is a natural preservative that increases the shelf life of foods. Patients with heart 
failure often feel fatigued and may have less energy to dedicate to the purchase and 
preparation of low-sodium food. Originally, we thought that purchasing fresh produce 
and meat may be prohibitively expensive for patients on fixed or limited incomes; 
however, income was not a statistically significant predictor of higher sodium excretion. 
Another important question is whether the guidelines should recommend varying 
amounts of sodium intake for people with heart failure with different body weight and 
other clinical characteristics. According to Gupta and colleagues (2012) there is still 
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uncertainty as to whether dietary sodium intake recommendations should be 
individualized. 9  
Diabetes was a strong predictor of higher than recommended sodium intake. This 
may be explained by the fact that any form of kidney disease in which tubular 
reabsorption of filtered sodium does not match the filtered load plus dietary intake can 
cause renal sodium wasting (ie: hyperfiltration occurring in earlier stages of diabetic 
nephropathy).13 The finding that diabetes is a predictor of higher sodium intake is 
consistent with a previous analysis in which patients with diabetes were four times as 
likely to consume more than 4 grams of sodium per day over time.53 This finding may be 
explained by the association between diabetes and obesity, in which case diabetes is 
acting as a marker of obesity.   
In the literature, associations between mild cognitive impairment and heart failure 
self-care behaviors are mixed.1, 54, 55 Mild cognitive impairment has been associated with 
worse self-care management 56, 57 probably because of an inability to perform the 
complex decision-making required to manage signs and symptoms. An association 
between cognitive impairment and poorer self-care maintenance such as eating a low 
sodium diet has not been reported. In a study by Cameron and colleagues, the majority of 
patients (73%) had unrecognized or sub-clinical cognitive impairment and were as likely 
to engage in health promoting behaviors, such as daily weighing, as those without 
cognitive impairment.57 Dickson and colleagues reported that poorer cognition was 
associated with better self-care behaviors among patients with heart failure in a mixed-
methods study.58 It is important to note that these prior studies focused on the subjective 
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assessment of multiple self-care behaviors and not exclusively on dietary sodium. 
Further, there were considerable differences across studies in the methods of measuring 
cognition that may, in part, explain differences in study findings.58  
While it may be assumed that patients with mild cognitive impairment will not be 
able to follow a low-sodium diet that was not the case in this study. Patients who were 
cognitively intact had more than double the odds of consuming higher than recommended 
sodium levels compared to patients with cognitive impairment. This seemingly counter-
intuitive finding may be explained by the fact that patients with cognitive impairment 
often have caregivers who make and provide their meals. Patients who are cognitively 
intact may be more self-reliant in making dietary decisions. This finding could also be 
explained by the rigidity that is associated with cognitive impairment.59, 60 Rigidity refers 
to the tendency to form and repeat particular behaviors; eating the same foods is one form 
of rigidity. We cannot confirm either of these hypotheses because we did not collect data 
on caregivers or rigidity associated with specific dietary choices in this study.  
Many patients with heart failure struggle to consume levels of sodium that are 
considered moderate. In a study of adults with heart failure from the Southern United 
States, only 33% of individuals consumed 2000 mg/day or less with the wide range of 
522 to 9251 mg/day.61 Likewise, based on 24-hour urinary sodium excretion levels, 
another study reported that 34% of the sample was compliant with recommendations to 
consume less than 3000 mg/day and only 15% consumed less than 2000 mg/day.10  
Recently sodium restriction for patients with heart failure has been questioned due 
to wide variation in the study protocols, study samples, fluid intake, measurement of 
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sodium intake and compliance.14 Some studies have even questioned any sodium 
restriction;62, 63 however, this was largely due to a very rigid definition of sodium intake 
(80 mmol/day).62 Paterna and colleagues recommend a normal sodium diet, defined as 
120 mmol/day (about 2800 mg/day) 62, 63 which is consistent with the recommendation of 
< 3g a day for patients with Class C and D HF.14 Overall, the message across these 
studies and a recent review by Gupta and colleagues is consistent— high sodium intake is 
not optimal for patients with heart failure because excessive sodium intake is associated 
with fluid retention; however, the lower-dose range of sodium intake needs to be better 
defined, and possibly individualized to patients in future studies.9  
Strengths and Limitations 
One of the strengths of this study was the repeated measures of sodium excretion 
on the same individuals over a six-month period. Multivariate statistical methods were 
used for these repeated measures to account for the correlation of measures within an 
individual, which reduced measurement error and individual variability.  The use of 
longitudinal data in this study also provided a clearer picture of how well patients 
followed a low-sodium diet over an extended period of time, instead of one point in time. 
Another strength of the study is that we used robust and transparent imputation methods 
to address potential bias from incomplete data.38, 40  
The study also had several limitations including the fact that this was a secondary 
analysis of a dataset that did not include measures of sodium intake. Data from carefully 
controlled studies show that at least 7 days of direct measurement of sodium intake and 
excretion in the urine are needed to achieve correlations of 0.8,64 which implies that food 
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records and urine excretion provide complementary information about sodium intake. 
The relationship between sodium intake and excretion is analogous to fasting blood 
glucose and hemoglobin A1c in diabetic patients. These two measures provide similar, 
but different, information about dietary adherence in patients with diabetes. In this study, 
our intention was not to precisely estimate sodium intake over the previous 24 hrs, but to 
estimate general adherence to dietary recommendations. For our purposes, 24-hour 
sodium excretion was the best available marker of dietary sodium consumption.  
Another limitation of this study was that patients in this sample were on loop 
diuretics, which enhance urinary excretion of sodium by inhibiting tubular reabsorption at 
the thick ascending limb of the Loop of Henle, in the nephron.13 Arcand and colleagues 
(2010), found no statistically significant relationship between 24-hour urine sodium 
excretion and sodium intake from food records in patients with heart failure on a loop 
diuretic; however, they reported significant correlations for non-heart failure cardiac 
patients and for patients with heart failure who were not prescribed a loop diuretic.65 
While informative, limitations of the Arcand study were that it used a cross-sectional, 
correlational design in a young, relatively small sample of patients with heart failure in 
which other relevant variables that may explain the differences in sodium excretion were 
not controlled. Though there may be some imprecision from using urinary sodium 
excretion as a measure of dietary sodium intake for patients on loop diuretics, it is still 
considered the best measure for patients with heart failure.10, 31, 66 In addition, we 
statistically controlled for diuretic use. 
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There are inherent limitations to a secondary data analysis, including the fact that 
this study was limited by the demographics and size of the original sample. For example 
this sample was younger than most other community dwelling samples of patients with 
heart failure so the results may not be generalizable to older adults with heart failure. 
There may be additional predictors of higher sodium intake that were not measured in the 
parent study, such as fluid intake, and thus could not be controlled for. In addition, while 
it was a strength that we used four of the five dimensions of adherence in the WHO 
model, the dimensions were not measured comprehensively. For instance, due to the 
sample size, we were restricted to including only variables that were both conceptually 
consistent with the WHO dimension as well as statistically associated with sodium 
excretion in the final model. Some dimensions may not have been fully captured by the 
variables selected.  
Conclusion 
 
Patients with heart failure who are cognitively intact, those who have diabetes or 
are obese are at risk for consuming more sodium than recommended. The 2013 Report of 
the AHA Guideline for the Management of Heart Failure recommends reasonable sodium 
restriction for patients with symptomatic HF to reduce congestive symptoms14 and the 
HFSA guidelines recommend that all patients with heart failure be provided with dietary 
instruction.5  Sodium dietary instructions should be contextualized within a longer 
conversation with patients about their general sodium intake. Further research may 
support identifying higher risk patients and intervening to help them decrease their 
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sodium intake. Ultimately, interventions around dietary sodium intake may help decrease 
their risk of decompensation and re-hospitalization.11, 67 
Implications for Practice  
• Patients who have diabetes, are obese or are cognitively intact might be at risk for 
consuming more sodium than recommended.  
• Further research should identify patients and intervene to help them reduce high 
sodium consumption with tailored dietary interventions.  
Acknowledgements 
The authors gratefully acknowledge Dr. Russell Localio, Associate Professor of 
Biostatistics at the University of Pennsylvania School of Medicine, for his substantial 
contribution to the mixed-effects and imputation methods of this paper. We also 
appreciate his commitment to interdisciplinary collaboration and the mentorship of 
students. The authors would also like to acknowledge Thomas A. Gillespie, MD, FACC 
for scoring the New York Heart Association interviews.  
  42 
References 
 
1. Riegel B, Lee CS and Dickson VV. Self care in patients with chronic heart 
failure. Nat Rev Cardiol. 2011; 19: 644-54. 
2. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated Into 
the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in 
adults. Journal of the American College of Cardiology. 2009; 53: e1-e90. 
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for 
the diagnosis and management of chronic heart failure in the adult: a report of the 
american college of cardiology/american heart association task force on practice 
guidelines (writing committee to update the 2001 guidelines for the evaluation and 
management of heart failure): developed in collaboration with the american college of 
chest physicians and the international society for heart and lung transplantation: endorsed 
by the heart rhythm society. Circulation. 2005; 112: e154-235. 
4. Riegel B, Moser DK, Powell M, Rector TS and Havranek EP. Nonpharmacologic 
care by heart failure experts. J Card Fail. 2006; 12: 149-53. 
5. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart 
failure practice guideline. J Card Fail. 2010; 16: e1-194. 
6. Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive 
heart failure exacerbations. Arch Intern Med. 2001; 161: 2337-42. 
7. Lennie TA, Worrall-Carter L, Hammash M, et al. Relationship of heart failure 
patients' knowledge, perceived barriers, and attitudes regarding low-sodium diet 
recommendations to adherence. Prog Cardiovasc Nurs. 2008; 23: 6-11. 
8. Chung ML, Moser DK, Lennie TA, et al. Gender differences in adherence to the 
sodium-restricted diet in patients with heart failure. J Card Fail. 2006; 12: 628-34. 
9. Gupta D, Georgiopoulou VV, Kalogeropoulos AP, et al. Dietary sodium intake in 
heart failure. Circulation. 2012; 126: 479-85. 
10. Lennie TA, Song EK, Wu JR, et al. Three gram sodium intake is associated with 
longer event-free survival only in patients with advanced heart failure. J Card Fail. 2011; 
17: 325-30. 
11. Arcand J, Ivanov J, Sasson A, et al. A high-sodium diet is associated with acute 
decompensated heart failure in ambulatory heart failure patients: a prospective follow-up 
study. Am J Clin Nutr. 2011; 93: 332-7. 
12. United States Department of Agriculture. Dietary guidelines for Americans, 2010. 
7th ed.: United States Department of Health and Human Services, 2011. 
13. Skorecki K and Ausiello D. 118 - Disorders of Sodium and Water Homeostasis. 
Goldman's Cecil Medicine (Twenty-Fourth Edition). Philadelphia: W.B. Saunders, 2012, 
p. 720-34. 
14. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the 
Management of Heart Failure: A Report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll 
Cardiol. 2013. 
15. Heo S, Lennie TA, Moser DK and Okoli C. Heart failure patients' perceptions on 
nutrition and dietary adherence. Eur J Cardiovasc Nurs. 2009; 8: 323-8. 
  43 
16. van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH and van 
Veldhuisen DJ. Compliance in heart failure patients: the importance of knowledge and 
beliefs. Eur Heart J. 2006; 27: 434-40. 
17. Bentley B, De Jong MJ, Moser DK and Peden AR. Factors related to 
nonadherence to low sodium diet recommendations in heart failure patients. Eur J 
Cardiovasc Nurs. 2005; 4: 331-6. 
18. Heo S, Moser DK, Lennie TA, Riegel B and Chung ML. Gender differences in 
and factors related to self-care behaviors: a cross-sectional, correlational study of patients 
with heart failure. Int J Nurs Stud. 2008; 45: 1807-15. 
19. World Health Organization. Adherence to long-term therapies: Evidence for 
action. Geneva, Switzerland: WHO, 2003, p.1-211. 
20. Riegel B, Lee CS, Ratcliffe SJ, et al. Predictors of objectively measured 
medication nonadherence in adults with heart failure. Circ Heart Fail. 2012; 5: 430-6. 
21. Rickham PP. Human Experimentation. Code of Ethics of the World Medical 
Association. Declaration of Helsinki. Br Med J. 1964; 2: 177. 
22. Riegel B, Moelter ST, Ratcliffe SJ, et al. Excessive daytime sleepiness is 
associated with poor medication adherence in adults with heart failure. J Card Fail. 2011; 
17: 340-8. 
23. Folstein M FS, McHugh P. Mini-mental state: a practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-98. 
24. Charlson ME, Pompei P, Ales KL and MacKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development and validation. J 
Chronic Dis. 1987; 40: 373-83. 
25. Riegel B and Carlson B. Is individual peer support a promising intervention for 
persons with heart failure? J Cardiovasc Nurs. 2004; 19: 174-83. 
26. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D and Unger A. Effect of a 
standardized nurse case-management telephone intervention on resource use in patients 
with chronic heart failure. Archives of Internal Medicine. 2002; 162: 705-12. 
27. Riegel B, Carlson B, Glaser D and Hoagland P. Which patients with heart failure 
respond best to multidisciplinary disease management? Journal of cardiac failure. 2000; 
6: 290-9. 
28. Kubo SH, Schulman S, Starling RC, Jessup M, Wentworth D and Burkhoff D. 
Development and validation of a patient questionnaire to determine New York Heart 
Association classification. J Card Fail. 2004; 10: 228-35. 
29. European Food Safety Authority. Opinion of the scientific panel on dietetic 
products, nutrition and allergies on a request from the commission related to the tolerable 
upper intake level of sodium. The EFSA Journal. 2005; 209: 1-26. 
30. Espeland MA, Kumanyika S, Wilson AC, et al. Statistical issues in analyzing 24-
hour dietary recall and 24-hour urine collection data for sodium and potassium intakes. 
Am J Epidemiol. 2001; 153: 996-1006. 
31. Korhonen MH, Jarvinen RM, Sarkkinen ES and Uusitupa MI. Effects of a salt-
restricted diet on the intake of other nutrients. Am J Clin Nutr. 2000; 72: 414-20. 
32. Song HJ, Cho YG and Lee H-J. Dietary sodium intake and prevalence of 
overweight in adults. Metabolism. 2013. 
  44 
33. Bingham SA, Williams R, Cole TJ, Price CP and Cummings JH. Reference values 
for analytes of 24-h urine collections known to be complete. Ann Clin Biochem. 1988; 25 
( Pt 6): 610-9. 
34. Intersalt cooperative research group. Intersalt: an international study of electrolyte 
excretion and blood pressure. Results for 24 hour urinary sodium and potassium 
excretion. Intersalt Cooperative Research Group. Bmj. 1988; 297: 319-28. 
35. Day NE, McKeown N, Wong MY, Welch A and Bingham S. Epidemiological 
assessment of diet: A comparison of a 7-day diary with a food frequency questionnaire 
using urinary markers of nitrogen, potassium and sodium. International Journal of 
Epidemiology. 2001; 30: 309-17. 
36. Institute of Medicine. Dietary reference intakes: applications in dietary 
assessment. Washington, D.C.: National Academies Press, 2000. 
37. Eshaghian S, Horwich TB and Fonarow GC. Relation of loop diuretic dose to 
mortality in advanced heart failure. Am J Cardiol. 2006; 97: 1759-64. 
38. Little RJ and Rubin DB. Statistical analysis with missing data. New York: John 
Wiley & Sons, 2002. 
39. Little RJ and Rubin DB. Statistical analysis with missing data. New York: John 
Wiley & Sons Inc., 1987. 
40. Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: John 
Wiley & Sons, Inc, 1987. 
41. Kenward M and Carpenter J. Multiple imputation: current perspectives. Statistical 
Methods in Medical Research. 2007; 16: 199-218. 
42. Royston P. Multiple imputation of missing values. The Stata Journal. 2004; 4: 
227–41. 
43. Royston P. Multiple imputation of missing values: update of ice. The Stata 
Journal. 2005; 5: 527-36. 
44. Fitzmaurice G., Laird N. and Ware J. Applied Longitudinal Analysis. New York: 
Wiley, 2004. 
45. World Health Organization. Overview: medication adherence--where are we 
today? Geneva, Switzerland: WHO, 2006, p. 7-16. 
46. Bodner TE. What improves with increased missing data imputations? Structural 
Equation Modeling: A Multidisciplinary Journal. 2008; 15: 651-75. 
47. StataCorp. Stata Statistical Software: Release 11.2. College Station, TX: 
StataCorp LP, 2009. 
48. Cocores JA and Gold MS. The salted food addiction hypothesis may explain 
overeating and the obesity epidemic. Med Hypotheses. 2009; 73: 892-9. 
49. Centers for Disease Control and Prevention. Sodium intake among adults - United 
States, 2005-2006. MMWR Morb Mortal Wkly Rep. 2010; 59: 746-9. 
50. Morris CD. Effect of dietary sodium restriction on overall nutrient intake. Am J 
Clin Nutr. 1997; 65: 687S-91S. 
51. Karppanen H and Mervaala E. Sodium intake and hypertension. Prog Cardiovasc 
Dis. 2006; 49: 59-75. 
52. Fonseca-Alaniz MH, Takada J, Andreotti S, et al. High sodium intake enhances 
insulin-stimulated glucose uptake in rat epididymal adipose tissue. Obesity (Silver 
Spring). 2008; 16: 1186-92. 
  45 
53. Masterson Creber RM, Lee CS, Lennie TA, Topaz M and Riegel B. Using growth 
mixture modeling to identify classes of sodium adherence in adults with heart failure. J 
Cardiovasc Nurs. 2013. 
54. Riegel B, Lee CS, Dickson VV and Carlson B. An update on the self-care of heart 
failure index. J Cardiovasc Nurs. 2009; 24: 485-97. 
55. Riegel B, Carlson B, Moser DK, Sebern M, Hicks FD and Roland V. 
Psychometric testing of the self-care of heart failure index. J Card Fail. 2004; 10: 350-
60. 
56. Lee CS, Gelow JM, Bidwell JT, et al. Blunted responses to heart failure 
symptoms in adults with mild cognitive dysfunction. J Cardiovasc Nurs. 2012. 
57. Cameron J, Worrall-Carter L, Page K, Riegel B, Lo SK and Stewart S. Does 
cognitive impairment predict poor self-care in patients with heart failure? Eur J Heart 
Fail. 2010; 12: 508-15. 
58. Dickson V, Lee C S and B R. How do cognitive function and knowledge affect 
heart failure self-care? Journal of Mixed Methods Research. 2011; 5: 167-89. 
59. Litvan I, Mohr E, Williams J, Gomez C and Chase TN. Differential memory and 
executive functions in demented patients with Parkinson's and Alzheimer's disease. J 
Neurol Neurosurg Psychiatry. 1991; 54: 25-9. 
60. Schultz PW and Searleman A. Rigidity of thought and behavior:100 years of 
research. Genetic, Social, and General Psychology Monographs. 2002; 128: 165-207. 
61. Frediani JK, Reilly CM, Higgins M, Clark PC, Gary RA and Dunbar SB. Quality 
and Adequacy of Dietary Intake in a Southern Urban Heart Failure Population. J 
Cardiovasc Nurs. 2013; 28: 119-28. 
62. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different 
dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical 
outcome in patients with recently compensated heart failure. Am J Cardiol. 2009; 103: 
93-102. 
63. Paterna S, Gaspare P, Fasullo S, Sarullo FM and Di Pasquale P. Normal-sodium 
diet compared with low-sodium diet in compensated congestive heart failure: is sodium 
an old enemy or a new friend? Clin Sci (Lond). 2008; 114: 221-30. 
64. Bates C, Thurnham D, Bingham S, Margetts B and Nelson M. Bio- chemical 
markers of nutrient intake. Oxford, England: Oxford University Press, 1997. 
65. Arcand J, Floras JS, Azevedo E, Mak S, Newton GE and Allard JP. Evaluation of 
two methods for sodium intake assessment in cardiac patients with and without heart 
failure: the confounding effect of loop diuretics. American Journal of Clinical Nutrition. 
2010; 93: 535-41. 
66. O'Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion 
and risk of cardiovascular events. JAMA. 2011; 306: 2229-38. 
67. Paul S. Hospital discharge education for patients with heart failure: what really 
works and what is the evidence? Critical Care Nurse. 2008; 28: 66-82. 
 
	  
 
  46 
  
CHAPTER III: USING GROWTH MIXTURE MOELING TO IDENTIFY CLASSES 
OF SODIUM ADHERENCE IN ADULTS WITH HEART FAILURE 
(Published: Journal of Cardiovascular Nursing) 
Masterson Creber R, Lee CS, Lennie TA, Topaz M, Riegel B. Using growth mixture 
modeling to identify classes of sodium adherence in adults with heart failure. J 
Cardiovasc Nurs. May-Jun 2014;29(3):209-217. 
 
Corresponding author: Masterson Creber R 
Statement of Author Contributions: Ruth Masterson Creber was the lead author of this 
article. She developed the study question, completed the analysis and drafted the article. 
Christopher S. Lee, PhD RN from Oregon Health & Science University assisted in the 
analysis and provided critical edits to the article. Terrie Lennie, PhD, RN from the 
University of Kentucky and Maxim Topaz, PhD RN from the University of Pennsylvania 
School of Nursing both made critical edits. Barbara Riegel, DNSc, RN from the 
University of Pennsylvania School of Nursing, Philadelphia, United States was the senior 
author of this article. She was the PI of the parent study and she provided critical edits for 
this article.  
Funding acknowledgement: This work was funded by the National Heart, Lung & 
Blood Institute (RO1 HL084394-01A1) and by the Philadelphia Veterans Affairs Medical 
Center, VISN 4 Mental Illness Research, Education, and Clinical Center. Ruth Masterson 
Creber was funded by the National Hartford Centers of Geriatric Nursing Excellence 
Patricia G. Archbold Scholarship program; the New Courtland Center for Transitions and 
  47 
Health and the Center for Integrative Science in Aging NIH/NINR (T32-NR009356) in 
2012; and an NIH/NINR F31 (NR014086-01) in 2013-2014.  
 
Abstract 
 
Background: The prevention of fluid retention is important to reduce hospitalizations in 
patients with heart failure. Following a low-sodium diet helps to reduce fluid retention. 
Objective: The primary objective of this study was to use growth mixture modeling to 
identify distinct classes of sodium adherence—characterized by shared growth 
trajectories of objectively measured dietary sodium. The secondary objective was to 
identify patient-level determinants of the nonadherent trajectory.  
Methods: This was a secondary analysis of data collected from a prospective longitudinal 
study of 279 community-dwelling adults with previously or currently symptomatic heart 
failure. Growth mixture modeling was used to identify distinct trajectories of change in 
24-hour urinary sodium excretion measured at three time points over six months. Logistic 
modeling was used to predict membership in observed trajectories.  
Results: The sample was predominantly male (64%), mean age 62 years, functionally 
compromised (59% NYHA class III), with non-ischemic HF etiology. Two distinct 
trajectories of sodium intake were identified and labeled adherent (66%) and non-
adherent (34%) to low-sodium diet recommendations. Three predictors of the non-
adherent trajectory were identified, confirming our prior mixed-effect analysis. 
Compared with normal weight patients (BMI <25), being overweight and obese was 
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associated with a 4-fold incremental increase in the likelihood of being in the non-
adherent trajectory (odds ratio (OR): 4.63, 95% confidence interval (CI): 1.66-12.91, 
p<0.002). Being less than 65 years of age (OR: 4.66, 95% CI: 1.04-20.81, p=0.044) or 
having diabetes (OR: 4.15, 95% CI: 1.29-13.40, p=0.016) were both associated with over 
four times the odds of being in the non-adherent urine sodium trajectory compared with 
people who were over 65 or without diabetes, respectively. 
Conclusions: Two distinct trajectories of sodium intake were identified in patients with 
heart failure. The non-adherent trajectory was characterized by an elevated pattern of 
dietary sodium intake shown by others to be associated with adverse outcomes in heart 
failure.  Predictors of the non-adherent trajectory included higher body mass index, 
younger age and diabetes.  
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Introduction 
 
Adherence to a low-sodium diet is an important self-care behavior for patients 
with heart failure (HF). Excess sodium intake promotes higher ventricular filling 
pressures, pulmonary congestion, clinical symptoms of fluid retention, and puts patients 
with HF at high risk for acute decompensation and hospitalizations. 1 As such, adherence 
to a low-sodium diet is a key factor in reducing hospitalizations2 and one of the most 
frequently recommended self-care behaviors. 3-6 Both the 2012 European Society of 
Cardiology and 2009 American College of Cardiology/American Heart Association 
guidelines recommend less than 2 g/day of dietary sodium. 7,8 Likewise, the Heart Failure 
Society of America recommends that all patients with clinical symptoms of HF restrict 
sodium to 2-3 g/day. 6 It is estimated, however, that only about 22-55% of HF patients 
are adherent to a low-sodium diet. 9-12 
Adherence, as defined by the World Health Organization (WHO), is a 
multidimensional phenomenon, determined by multiple dimensions related to social and 
economic conditions, the health care system in addition to condition, therapy or patient-
related factors.13 Like medication adherence in this patient population, adherence to a low 
sodium diet is influenced by a number of factors.14 Although several factors have been 
associated with non-adherence to a low-sodium diet in the adult population with HF, 
there are limitations to these research findings. Most prior studies on 24-hour urine 
sodium excretion are cross-sectional in design and conducted with small samples. 
Deterministic methods, including mixed effects modeling have previously been used to 
identify patient-level factors associated with high sodium intake using an a priori 
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determined cutoff of adherence.15 This study builds on that analysis by applying a growth 
mixture modeling methodology to identify the “most likely” trajectory membership and 
quantify uncertainty in trajectory membership over time. 
The specific aim of this study was to use growth mixture modeling to identify 
distinct patterns of change in 24-hour urine sodium excretion, as a proxy for dietary 
sodium intake, over six months of observation. The secondary aim was to build on a 
previous mixed effects analysis15 and examine patient-level determinants of observed 
trajectories of urine sodium. 
Methods 
 
Design and Study population 
The methodology of this study has been previously reported in detail. 14 In brief, 
this was a prospective, observational study of the association between excessive daytime 
sleepiness and HF self-care among 279 community-dwelling adults with chronic HF. The 
participants were enrolled from three outpatient settings in Philadelphia, Pennsylvania 
and Newark, Delaware between 2007 and 2010. Most of the participants were followed 
in specialty HF clinics and most were on optimal medical therapy.  Given the 
observational nature of this study, the usual care provided by HF specialty clinics was not 
augmented. Participants did not receive supplemental HF self-care education outside of 
what was provided as part of routine care. 
Inclusion criteria for the study specified adults with previously or currently 
symptomatic HF confirmed by echocardiographic and clinical evidence. 14 The 
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participants needed to be able to actively participate in the study, so inclusion criteria 
specified that patients must be able to read and speak English and have sufficient 
cognition and health literacy to complete the questionnaires. Otherwise eligible 
individuals were excluded if they lived in a long-term care setting and were not 
responsible for their own self-care, including preparing and making choices about food. 
People were also excluded if they had renal failure requiring dialysis, imminent plans to 
move out of the area, a history of drug or alcohol abuse within the past year or an 
imminently terminal illness. People with major depressive illness were also excluded 
because self-care behaviors are influenced by major depression. 16 This study was in 
compliance with the Declaration of Helsinki. 17 Institutional Review Board approval was 
obtained from all three sites and all participants gave written informed consent. Data 
were collected at baseline, 3-and 6-months by research assistants during home visits. 
Institutional Review Board approval was obtained for this secondary analysis.  
Measurement of dietary sodium 
A 24-hour urine sodium collection is considered a reliable and valid estimate of 
sodium intake 18,19 and has been used as an objective measure of sodium intake in other 
studies with patients with HF. 1,20 Sodium is under tight homeostatic control. If 
individuals do not perspire heavily, urine sodium accounts for approximately 95% to 
98% of daily dietary sodium intake. 21 Variations in 24-hour urine sodium are primarily 
attributed to changes in sodium intake over the previous 24 hours.22 Daily urine sodium 
levels are estimated to fluctuate only about 11%. 23 Validation for 24-hour urine 
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collection has been performed by urine recovery of oral doses of para-amino benzoic 
acid.19,23,24  
The methodology for collecting and measuring dietary sodium intake has been 
reported elsewhere 15 and is summarized here. Dietary sodium intake was estimated using 
three 24-hour urine sodium levels measured at enrollment, and at three and six months 
after enrollment. The procedure for the collection and quantification of the 24-hour urine 
samples is summarized here. At the time of enrollment, participants and their family 
members were given training for the specimen collection. Participants were provided 
with all necessary supplies including: urine containers, collection devices, verbal and 
written instructions (with pictures) specifying when they should start and finish collecting 
the specimen. Prior to each urine collection, patients were given a reminder call and 
training for the procedure was reinforced by the research assistant. Participants self-
reported the start and stop time of the urine collection. If the recorded time was less than 
22 hours or greater than 26 hours it was considered inaccurate and excluded from the 
analysis. Specimens were collected from participant’s homes by a courier service shortly 
after the 24-hour sample was complete.15  
Urine sodium analyses were completed at the central laboratory at the Hospital of 
the University of Pennsylvania using the ion-selective electrode method (Beckman LX® 
20 Chemistry Analyzer, Beckman Coulter, Inc., Fullerton, CA) to determine the amount 
of sodium in the urine specimens. A normal urinary sodium level is 40 to 120 
mEq/L/day. 11 In order to compare urine excretion with the recommended diet of 2-3 
g/day sodium intake, 6 urine sodium excretion in millimoles was converted to g (g= 
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mmol* .02299) to estimate dietary sodium intake. As a quality assurance measure, 
urinary creatinine was measured concurrently. Normal urinary creatinine is 1 ± 10% g 25 
so any samples with creatinine levels <0.9 g in 24 hours were considered incomplete.26  
Statistical Analysis 
Standard descriptive (proportions, means and standard deviations), unadjusted 
odds ratios and t tests were used to describe the sample and compare trajectories. Latent 
growth mixture modeling was used to identify distinct trajectories of urinary sodium 
using data from three time points. 
Latent class growth modeling is used to examine patterns in longitudinal data with 
repeated measures to identify classes or subgroups within a population. Unique 
trajectories or pathways differentiate classes from one another. Using repeated measures 
to identify subgroups within a population has been used across multiple disciplines. 
Latent class growth mixture analysis also has been used across multiple disciplines to 
identify trajectories of development; 27 nighttime continence;28 physical aggression in 
young boys;29 the natural history of prostate disease;30 depression recovery profiles31 and 
preventative interventions for reducing classroom violence. 32 It has also been used 
extensively in the substance abuse literature to identify trajectories and predictors of 
high-risk behavior.33-44 Within the heart failure literature, it has been used to identify 
patterns of cognitive change,45 as well as patterns of medication nonadherence. 46  
The purpose of growth mixture modeling is to identify homogenous subgroups 
within larger heterogeneous populations and represent unobserved heterogeneity among 
subjects in a sample. Finite mixture random effects are used to represent the departure of 
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individuals’ latent growth parameters from the population mean growth parameter. 32,47 
Class membership of an individual cannot be measured directly; however, it can be 
inferred based on membership in a specific trajectory.48 According to Wang and 
colleagues growth mixture modeling can be described as having three steps. The first step 
is analogous to random effects modeling which specifies individual-level observed data 
as a sum of fixed effects, random effects and measurement errors at each observation 
point. 48 The second step represents the distribution of class-specific random effects and 
covariate effects on class-specific mean growth trajectories. The third step includes the 
covariate effects on class membership using regression models. 48 
Growth mixture modeling has many benefits over alternative methods, as 
reviewed by Preacher.49 Growth mixture modeling can model changes in factors over 
time as random effects, allow for variations between individuals and subgroups (instead 
of individuals and the population average as in mixed-effect modeling) and judge 
comparative fit between iterative models with various statistics; the focus of growth 
mixture modeling is on capturing inter-and-intra-individual differences over time.50 
Conventional deterministic approaches minimize within group and maximize between-
group variance. In contrast, growth mixture modeling employs a model-based approach 
to calculate the probability of membership in each trajectory, identify “most likely” 
trajectory membership, and quantifies uncertainty in trajectory membership.  In this 
article the terms subgroups and classes are used synonymously to describe people who 
share a specific growth trajectory. 
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Growth mixture modeling was performed using MPlus v.6.12 (Los Angeles, CA). 
Model fit between 2 to 4 trajectories were compared (k vs k-1 trajectories) using the Lo-
Mendell-Rubin adjusted likelihood ratio test (p<0.05), parametric bootstrapped likelihood 
ratio test (p<0.05), Bayesian Information Criteria (BIC), convergence (entropy closest to 
1.0), the proportion of the sample in each trajectory (not less than 5%), and average 
posterior probabilities (closest 1.0). 50,51 Predictors of observed trajectories of dietary 
sodium were quantified using logistic regression modeling in MPlus. Unadjusted and 
multivariate odds ratios (OR) and 95% confidence intervals (CI) were calculated for each 
model factor, taking into account our method of multiple imputation, described below. 
The following ten determinants of non-adherence were tested based on the five 
dimensions of adherence posed by the WHO.52 Four of the five WHO adherence 
dimensions were included in this analysis. The fifth factor was not included because data 
on the health care system was not available for this secondary data analysis. Patient 
related factors included gender, age and BMI. Social and economic factors included race, 
income and highest level of education. Condition related factors included New York 
Heart Association (NYHA) functional class, HF type (diastolic or systolic), etiology of 
HF and diabetes as a comorbidity. Therapy related included diuretic use.  
Robust Handling of Missing Data 
In an effort to reduce bias, a principled method of multiple imputation53 was 
performed to account for missing urine sodium excretion values (23% of the sample had 
at least one missing value). Data were imputed using the method of chained equations 
(Stata v. 11.2). 54-56 The method of chained equations is a contemporary technique that 
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imputes missing data based on multiple covariates in the dataset (i.e. a full information 
method of imputation). The latent class variable was fit on imputed data in Mplus v.6.12. 
Multiple sensitivity analyses were performed to examine potential differences in the 
significance and effect size of predictors of urine sodium trajectories comparing complete 
case with imputed data samples. There were no differences in the predictors identified in 
the models except for the size of the confidence intervals; thus, for economy of 
presentation, only the final analysis using imputed data is shown here.  
Results 
 
The overall demographic and clinical characteristics of the sample population 
overall at baseline are presented in Table 3.1. This sample of adults (n=279) with HF was 
predominantly male (64%), had a mean age of 62, non-ischemic HF etiology and was 
functionally compromised (59% NYHA class III). The unadjusted odds ratios for the 
analysis are presented in Table 3.2. The covariates that had a statistically significant 
unadjusted association with the non-adherent trajectory were diabetes (p=0.008), income 
(p=0.031) and BMI (p<0.001).  
Modeling of three and four trajectories resulted in poor model fit and small 
trajectories (data not shown). Entropy for the two-class model was 0.752 and there were 
high average posterior probabilities of membership in both trajectories (94% and 91%), 
indicating very limited uncertainty in trajectory membership.  Based on the observed 
characteristics, we labeled the first and largest trajectory “adherent” (n=178, 66%) and 
second trajectory “non-adherent” (n=91, 34%).  
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Table 3.1: Characteristics of the overall sample at baseline (n=279) 
 Overall n (%)  Overall n (%) 
Age   Diuretic  
    <   65 years 165  (59)     Yes 225 (81) 
    >=65 years 114  (41)     No   54 (19) 
Gender 
    Male 
    Female 
 
179 (64) 
Cognitive Impairment* (n=271) 
   Yes 
 
107 (40) 
100 (36)    No 164 (61) 
Race 
    Black/Other 
    White 
 
104 (38) 
Heart failure type 
    Diastolic/Mixed 
 
  86 (31) 
175 (63)     Systolic 193 (69) 
Income  
     More than needed 
     Enough to meet needs 
     Less than needed 
 
98 (35) 
Body mass index * (n=278)    
   Normal 
 
  74 (26) 
      137 (49)    Overweight   73 (26) 
44 (16)    Obese 131 (47) 
NYHA functional class          
    Class I+II 
    Class III 
    Class IV 
 
65 (23) 
Highest level of education 
    Less than high school 
 
  27 (10) 
      164 (59)     High school graduate 102 (37) 
50 (18)     More than high school 150 (54) 
Heart failure etiology   Diabetes   
    Ischemic HF 102 (37)    Yes 171 (61) 
    Non-ischemic HF 177 (63)    No 108 (39) 
Hypertension  COPD  
  Yes 180 (65)    Yes 58 (21) 
   No   99 (35)    No      221 (79) 
NYHA = New York Heart Association, COPD = Chronic obstructive pulmonary disease 
*Variables containing missing data 
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CI = confidence intervals, NYHA = New York Heart Association, LVEF = Left Ventricular Ejection 
Fraction, *Variables containing missing data 
 
As displayed in the Figure 3.1 there was heterogeneity within each trajectory, as 
demonstrated by the error bars, which indicate two standard deviations around each mean 
urine sodium level at each point in time. Paired t-tests demonstrate statistically significant 
differences between the two trajectories at each time point (p<0.001). Those in the 
adherent group started off at baseline with a mean sodium consumption of 2.42 g/day 
(standard deviation (SD) ±0.19, 95% CI: 2.39-2.45) versus 4.41 g/day (SD: ±0.34, 95% 
CI: 4.33-4.48) in the non-adherent trajectory (t=61.68, p<0.001). At three months, the 
Table 3.2: Unadjusted odds of membership in the non-adherent urine 
sodium trajectory (n=279) 
 Unadjusted 
Odds Ratio 
95% CI p-value 
Gender     
   Female  (reference)  
   Male 1.51 0.57-4.03 >0.2 
Body Mass Index    
   Normal  (reference)  
   Overweight 5.27 2.23-13.06 <0.001 
Age     
   >=65 years  (reference)  
    <  65 years 4.80 0.45-51.80 0.20 
Diabetes    
   No  (reference)  
   Yes 3.71 1.41-9.80 0.008 
Race      
   White  (reference)  
   Black/Other 2.60 0.97-7.00 0.059 
Income  2.07 1.07-4.02 0.031 
NYHA Functional Class  1.27 0.69-2.37 >0.20 
Heart failure etiology  1.57 0.37-6.68 >0.20 
Heart failure type 2.68 0.89-8.03 0.078 
Diuretic 3.58 0.35-36.62 >0.20 
Cognitive Impairment *n=271 1.00 0.44-2.27 >0.20 
LVEF  *n=278 0.99 0.97- 1.00 0.089 
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mean difference between the two trajectories was 2.16 g/day (SE: 0.36, t=59.99, 
p<0.001) and by six months was 1.98 g/day (SE: ±0.03, t=62.56, p<0.001). Within the 
adherent and non-adherent trajectories there were no differences from baseline to 6 
months (SE: ±0.02, t= -1.39, p=0.166 and SE: ±0.05, t= -0.47, p=0.640), indicating that 
there were limited changes in dietary sodium intake over time. 
Figure 3.1: Trajectories of adherence to a low-sodium diet 
 
Based on the WHO model, predictors of membership in the non-adherence 
trajectory were identified. The conceptual model was also supported using data driven 
statistical approaches including univariate associations. Compared with normal weight 
patients (BMI <25), being overweight and obese was associated with a 4-fold incremental 
increase in the likelihood of being in the non-adherent trajectory (OR: 4.63, 95% CI: 
1.66-12.91, p<0.002). Being less than 65 years of age (OR: 4.66, 95% CI: 1.04-20.81, 
p=0.044) or having diabetes (OR: 4.15, 95% CI: 1.29-13.40, p=0.016) were both 
associated with over four times the odds of being in the non-adherent urine sodium 
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trajectory compared with people who are over 65 or do not have diabetes, respectively.  
There were no significant differences in the odds of being in the non-adherent trajectory 
based on gender, cognition, diuretic use, income level, education, race, HF etiology, HF 
type or NYHA functional status.  
Discussion 
 
The primary aim of this study was to identify trajectories of sodium adherence in 
a sample of community dwelling HF patients and two groups were identified. Based on 
the more liberal Heart Failure Society of America sodium recommendations of 3g/day 
sodium intake, 6 one trajectory was labeled “adherent” and the other “non-adherent” to a 
low sodium diet. Both groups were consistently adherent or non-adherent over six 
months of follow-up. That is, there was no change in the level of adherence or non-
adherence over time. 
 To the best of our knowledge, this is the first study that describes adherence to a 
low-sodium diet using a growth mixture approach; however, this method has been 
applied to medication adherence in this study sample. 46 The predictors of the non-
adherence to a low sodium diet were being overweight or obese, age less than 65 years 
and having diabetes. These results that obesity and diabetes predict higher sodium 
consumption are consistent with an analysis that employed a mixed-effect analytic 
approach;15 however, in this study we also identified younger age as a risk factor for 
being non-adherent to a sodium restricted diet.  
HF patients who were overweight or obese, age less than 65 years or have 
diabetes were identified as being more likely to have trouble following a restricted 
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sodium diet and may need more focused, tailored self-care interventions.57 One approach 
to tailoring self-care interventions that we are testing in a pilot randomized control study 
is a tailored motivational interviewing and skill-building approach to improving self-care 
behaviors including adherence to a low-sodium diet. 
The finding that being obese is strongly associated with greater odds of being 
non-adherent to a restricted sodium diet implies that these patients may be consuming 
more food and by default more sodium, or that they are specifically consuming more 
foods that are higher in sodium. This finding is consistent with the Intersalt international 
study of electrolyte excretion and blood pressure, in which investigators reported a 
positive correlation between BMI and sodium excretion.19 They proposed that overweight 
individuals consuming higher sodium intake most likely explains this finding. 58 In 
contrast, Chung et al 20 found no differences in BMI between people who self-reported 
being adherent or  non-adherent to low-sodium guidelines. The approach in our study is 
different than that used by Chung and colleagues in that we did not apply a 2,000 mg 
cutoff for sodium adherence. Instead, we identified distinct and naturally occurring 
trajectories of urinary sodium excretion that happened to track with current dietary 
sodium recommendations.  Moreover, the current study was longitudinal in design. Thus, 
methodological differences may explain our incongruent findings.  
Other authors studying sodium adherence in the HF population have not reported 
our finding of an association between younger age and non-adherence to a low sodium 
diet. In studies of adherence to self-maintenance behaviors, an association between age 
and adherence to medication has been reported. Several studies report that younger 
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patients are more adherent to taking medication 59,60 while others found no consistent 
difference in medication adherence by age. 61-63 In this specific sample, we found no 
difference in overall medication adherence by age. 64 The association with younger age 
and the non-adherent trajectory could be that younger patients with HF may also be more 
newly diagnosed and not yet adept in the skills of identifying and avoiding hidden 
sodium in foods. Patients with HF who are over 65 years may be living that long because 
they have been more stringent with the self-maintenance behavior of eating a low salt 
diet.  
The finding that diabetes is a strong predictor of the non-adherence to a low 
sodium diet is most likely explained by overconsumption of sodium, rather than a 
physiologic mechanism. In fact, in the diabetic state of hyperinsulinemia, sodium 
reabsorption is enhanced in the nephron segments of the kidney. 65-68 Clinically, patients 
with both HF and diabetes may struggle to closely monitor both their sugar and their 
sodium intake. There may receive conflicting messages from multiple providers about 
nutritional priorities. The implications of this finding may be that interventions are 
needed to specifically address the dietary complexities of managing both HF and diabetes 
in this patient population.  
Several factors that we anticipated would predict sodium adherence did not reach 
statistical significance, including higher income and education. We expected that people 
who reported having inadequate income would potentially be more likely to be non-
adherent to a low sodium diet because low-sodium food is more expensive and time 
consuming to prepare than processed, higher-sodium foods; however, there were no 
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differences between people who reported more income than needed, enough to meet 
needs or less than needed. Several investigators have suggested that people with more 
years of education would be more adherent with medication; 62,69 however, education has 
not been found to be associated with sodium adherence. In this study, we found no 
differences in sodium adherence based on education. The lack of association between 
years of education and adherence to low-sodium diet is consistent with the propositions 
of the WHO adherence model,13 which suggests that higher education in and of itself 
does not necessarily lead to higher health literacy or behavior change. In this specific 
study, poor health literacy was an exclusion criterion. As an observational study, there 
was also no intervention tested, limiting our ability to comment on behavior change.  
There are probably many other barriers to following a low-sodium diet that are 
more important than knowledge. For instance, an identified barrier for patients is the 
perception that foods will taste bland and unappealing without added salt.57 This barrier 
has been addressed by clinicians who promote flavoring with salt substitutes, using low-
sodium cook books and allowing taste buds to adapt to lower-sodium foods.70 Other 
contextual barriers identified in a qualitative descriptive study of older women with 
hypertension and HF include eating alone with no motivation to cook healthy meals. 
These women also identified that healthcare providers need to provide more education on 
a low-sodium diet, as well as large-print informational materials.71 A study by De Brito-
Ashurt (2011) identified barriers to dietary sodium restriction in people of Bangladeshi 
origin with chronic renal disease living the UK.72 Though the disease and patient 
population are different from this study population, the barriers, including deeply rooted 
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dietary beliefs, attitudes and culturally established taste for salt,72-74 are likely to be 
universal across patient populations. 
Other authors found low-sodium diet adherence rates to be about 28% or 29%. 
11,12 The findings from this study offer a different perspective from that of population-
average adherence. What we can say is that 66% of the sample fit the adherent profile to 
sodium recommendations and 34% fit the non-adherent profile. These numbers cannot be 
compared with other population averages or direct calculations of sodium adherence. 
This non-deterministic approach offers advantages to understanding how non-adherence 
can be examined and provides a list of useful predictors that are relevant to clinicians for 
tailoring self-care interventions and education.  
Strengths and Limitations 
The primary strength of this study is the use of growth mixture modeling, which 
enables moving away from quantifying the overall population average to examining and 
quantifying heterogeneity and identifying distinct subgroups. Another strength of this 
research is that it includes longitudinal data collected at three time points, on a relatively 
large group of community dwelling stable patients with HF. Many other studies that have 
examined sodium adherence included only one, 24-hour urine collection in small sample 
sizes. With an even larger sample size, we may have been able to identify more latent 
categories of adherence and more predictors of trajectory membership. Further research is 
needed to determine if the two classes identified in this study will hold across multiple 
populations of patients with HF. In other words, are these predictors consistent and 
generalizable to different populations of patients with HF, or localized findings? The 
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primary limitation of this dataset was that originally 23% of the total sample had missing 
outcome data; however, this was accounted for, at least in part, by contemporary and 
robust imputation techniques.  
 
Conclusion 
 
  Two distinct trajectories of sodium intake were identified. The non-adherent 
trajectory identifies a distinct pattern of dietary sodium intake that is not consistent with 
current sodium guidelines. Identified predictors (overweight or obese, less than 65, or 
having diabetes) can be used by clinicians to target interventions to patients who are most 
likely to struggle with eating a lower sodium diet. Results can also be used to tailor 
interventions and patient education programs to the highest risk groups. They can also be 
incorporated into HF management programs. Future studies identifying the specific 
barriers within these patient populations are also warranted so that the specific barriers 
can be targeted with interventions.  
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Abstract 
 
Background: Regular exercise is recommended to improve physical function in patients 
with heart failure (HF). Exercise is known to decrease inflammation and thought to 
decrease myocardial stress. Studies of N-terminal pro b-type natriuretic (NT-proBNP) 
and high-sensitivity C-reactive protein (hsCRP) have been mixed in patients with HF. A 
multi-marker analysis may help identify distinct subgroups of HF patients who respond to 
exercise. The primary study objective was to identify common and distinct patterns of 
change in serum biomarkers of hsCRP and NT-proBNP and quantify the influence of 
exercise therapy on the patterns of change.  
Methods and Results:  NT-proBNP and hsCRP were assessed in a random sample of 
320 participants from the biomarker sub-study of the HF-ACTION study, a randomized 
clinical trial of exercise training versus usual care in patients with stable and chronic HF. 
Growth mixture modeling was used to identify unique biomarker patterns measured over 
12-months. Three statistically independent and clinically meaningful biomarker patterns 
of NTproBNP and hsCRP were identified. The largest “lowest and improving,” pattern 
(61%) had the lowest levels of NT-proBNP and hsCRP at baseline, with declines over 
time. The second “elevated and stable” pattern (34%) had higher hs-CRP and consistent 
NT-proBNP over time. The smallest and most deleterious “elevated and worsening” 
pattern (5%) had the highest levels of NT-proBNP and increasing hsCRP (p<0.001) over 
time. Participants randomized to the exercise intervention were much less likely to have 
the elevated/worsening pattern of NT-proBNP and hsCRP (relative risk ratio: 0.23, CI: 
0.06-0.92, p=0.037).  
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Conclusions: Exercise therapy was protective for reducing the frequency of membership 
in the worst pattern, indicating that exercise may help slow the progression of HF.  
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Introduction 
 
Exercise therapy is considered a safe non-pharmacological intervention to 
improve functional capacity1 and clinical outcomes2 for adults with heart failure. 
Moderate exercise routines (3 to 7 metabolic equivalent hours per week) are associated 
with a decreased risk of clinical events.3 Physiologically in patients with heart failure, 
exercise training improves myocardial contractility, perfusion, endothelial dysfunction,4,5 
angiogenesis,6 and coronary and peripheral skeletal vessel dilation.7 A challenge to the 
broad implementation of exercise training in heart failure is physiologic heterogeneity in 
response to exercise. That is, some patients respond to exercise therapy with reductions in 
peripheral hypoxia,8 local inflammation9 and resting heart rate,10 while others do not. 
Accordingly, the primary aim of this study was to identify common and distinct patterns 
of change in serum biomarkers of systemic inflammation and myocardial stress among 
adults with stable heart failure who participated in an exercise trial. The secondary aim of 
this study was to identify socio-demographic and clinical predictors of the most 
unfavorable patterns of change in biomarkers of systemic inflammation and myocardial 
stress. We hypothesized that exercise therapy would be associated with more favorable 
patterns of change in biomarkers over time.  
Methods 
 
Study population 
This was a secondary data analysis of a random selection of 320 participants from 
the complete cases of the biomarker sub-study of Heart Failure: A Controlled Trial 
Investigating Outcomes of Exercise Training (HF-ACTION) randomized control trial. 
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The full study design has been published previously.2,11 Briefly, HF-ACTION was a 
multicenter, randomized control trial designed to examine long-term safety and efficacy 
of aerobic exercise training in a large sample of medically stable, chronic outpatients with 
heart failure. Enrollment criteria included reduced left ventricular ejection fraction 
(LVEF) of 35% or less, New York Heart Association (NYHA) class II to IV and 
willingness to undergo exercise training. Patients were excluded if they could not 
exercise, were already habitual exercisers or had a cardiovascular event in the preceding 
6 weeks. Participants were randomized from 82 centers within the United States, Canada 
and France from 2003-2007 to a usual care or aerobic exercise-training group. The 
intervention entailed 36 supervised sessions followed by home-based training.  
All participants were to perform a maximal exercise test with gas exchange 
measurements on a treadmill, using the modified Naughton protocol, or a cycle 
ergometer, using a 10-Watt/min ramp protocol.12  Functional exercise capacity was 
measured at baseline by peak oxygen consumption (peak VO2).11 Blood samples were 
collected from a peripheral vein into EDTA-containing tubes, centrifuged immediately 
and stored at −70°C. 11 All samples were obtained on the same day but prior to exercise 
testing at the baseline, 3-month, and 12-month visits.13 Assays for all biomarkers were 
performed using commercially available assays (Roche Diagnostics, Inc.) at the Duke 
University central core laboratory.13 Socio-demographic and clinical history 
characteristics were self-reported at baseline and patients completed the EuroQol-5D 
(EQ-5D) as a measure of baseline health status.11 
The HF-ACTION randomized control trial was approved by all relevant 
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institutional review boards at the participating centers and the coordinating center.11 This 
study was also approved by institutional review boards at the University of Pennsylvania 
and Duke University. 
Biomarker measures 
High-sensitivity C-reactive protein (hsCRP) (mg/L) was selected as a marker of 
inflammation because it is associated with heart failure severity.14,15 N-terminal pro b-
type natriuretic (NT-proBNP) (pg/mL) was selected as a marker of myocardial stress and 
hemodynamic congestion because it is released in response to ventricular dilation, 
hypertrophy and wall tension16 and increases with the severity of ventricular 
dysfunction.17 NT-proBNP is also used routinely in the clinical management of patients 
with heart failure and is an indicator of heart failure progression.13,18,19 In addition, 
standard, reproducible and cost-effective assays are available for both biomarkers, 
making them useful for prognostication.20,21 Both assays were also available in the HF-
ACTION repository. Troponin was initially considered for this analysis, but was not 
included because there were concerns about the analytic sensitivity and lack of variability 
(zero-inflation) of the assay.   
Statistical Analysis 
 In the preliminary analysis, descriptive statistics of frequency, central tendency and 
dispersion over time were used to describe hsCRP and NT-proBNP independently.  
Mean values of ln(hsCRP) and ln(NT-proBNP) values were compared between the 
exercise training and usual care groups using analysis of covariance (ANCOVA), 
controlling for baseline biomarker values and treatment allocation. Heterogeneity within 
  77 
each biomarker was further examined using histograms, box-, dot- and spaghetti-plots. 
Consistent with previous HF-ACTION publications,13,22  raw values of NT-proBNP and 
hsCRP were log-transformed to approximate normality.  
  The primary aim of this study was to identify common and distinct patterns of 
change in ln(hsCRP) and ln(NT-proBNP). We chose to use growth mixture modeling to 
facilitate a multi-marker, multi-mechanism analysis of the serum biomarkers of systemic 
inflammation and myocardial stress.23-26 Though traditionally biomarkers have been 
considered individually,16  multi-marker strategies are now recommended to improve risk 
stratification and prediction in chronic heart failure.16,27,28 
Figure 4.1 Conceptual Model 
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 Growth mixture modeling is a model-based naturalistic approach used to identify 
distinct and common patterns of change over time within one or more measures (Figure 
4.1). Growth mixture modeling allows for the identification of previously unobserved 
patterns of change that have unique means, variances and homogeneous within-pattern 
growth. The benefits of this modeling approach specific to this study are that multiple 
patterns can be identified, missing data are handled with full-information maximum 
likelihood estimation, and patterns are not reliant on equally spaced time intervals.29 
Model selection was guided by the procedures explained by Ram and colleagues29 and 
detailed in Table 4.1.  
Table 4.1: Model fit criteria for latent class models 
   1 The Lo-Mendell-Rubin adjusted likelihood ratio test (p<0.05), indicating additive 
information from models with k vs. k-1 patterns of change 
2 Parametric bootstrapped likelihood ratio test (p<0.05), indicating additive information 
from models with k vs. k-1 patterns of change 
3 Bayesian Information Criteria and Akaike information criterion, with smaller numbers 
indicating better comparative fit 
4 Convergence (model entropy closer to 1.0) 
5 The proportion of the sample in each pattern of change (not less than 5% of the sample) 
6 Posterior probabilities (average probability of belonging in “most likely” pattern of change 
closet to 1.0) 
 
 Individual growth mixture models for ln(NT-proBNP) and ln(hsCRP) were 
identified and integrated into a single biomarker latent class model, which was 
characterized by three distinct biomarker patterns. Baseline characteristics of the patterns 
were described using medians (interquartile ranges) or means (SD) and frequencies 
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(proportions) where appropriate. Comparisons of characteristics among the biomarker 
patterns were made using χ2 analysis or one-way analysis of variance depending on levels 
of measurement.  
 The second aim of the study was to identify socio-demographic and clinical 
predictors of the individual unfavorable biomarker patterns of change. A model 
comparison approach30 was applied throughout the model building process starting with 
covariates associated in bi-variate analyses with the outcome variable (p<0.05). Next, a 
priori factors were added and factors associated with the outcome using a forward 
(starting with an empty model) and backwards (starting with a full model) stepwise 
selection approach were added. Variables were eliminated conservatively in a sequential 
approach if they had a p-value over 0.20. Factors that were considered in the models but 
were not significant and did not contribute to the robustness of the model were removed. 
The covariates included in the final model were the following 17 variables: 
randomization to the exercise intervention or usual care, gender, race, age, heart failure 
etiology, baseline creatinine, baseline peak VO2, body mass index (BMI), pain and 
anxiety (assessed with the EQ-5D), diabetes, hypertension, taking a loop diuretic, 
implantation of a pacemaker, bi-ventricular pacer or implantable cardioverter-
defibrillator, treatment with an angiotensin-converting-enzyme inhibitor (ACE) or 
angiotensin II receptor blocker (ARB). BMI was evaluated as a categorical variable and 
continuous linear, quadratic and log transformed variable. The continuous linear form of 
the variable was included in the model because neither the quadratic nor the log 
transformed continuous variables were statistically significant. 
Multinomial and logistic regression were used to identify predictors of observed 
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patterns and relative risk ratios (RRR), odds ratios (OR) and 95% confidence intervals 
(CI) were quantified and reported. Level of significance was set to p<0.05. Model fit was 
compared among multiple models using a χ2 likelihood ratio test, pseudo R2, AIC, and 
BIC tests as well as post-estimation fit statistics. StataMP v11.2 (College Station, Texas) 
was used for descriptive and comparative statistics, multinomial regression and logistic 
regression models. All mixture modeling was completed using Mplus (version v.7.0, Los 
Angeles, CA). ANCOVA models that used the baseline biomarker value as the single 
covariate were used to test for differences between the usual care and intervention 
groups’ mean ln(NTproBNP) and ln(hsCRP) values at baseline, 3-and 12-months, 
respectively.  
Results 
 
Baseline characteristics for this study cohort are reported in Table 2. Overall, the 
median age was 58 years, the majority of the sample was male (73%), NYHA class II 
(71%) with a median left ventricular ejection fraction (LVEF) of 24. Just over one-third 
of participants had a history of diabetes (34%) or previous myocardial infarction (39%) 
and approximately two-thirds had hypertension (60%). The vast majority of participants 
in this study were treated with evidence-based therapies, including over 95% on an ACE 
or ARB. Almost 50% of the sample was on a statin medication and almost 14% had an 
implanted biventricular pacemaker.  
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Table 4.2: Baseline demographic and clinical characteristics by biomarker patterns of change at baseline n=320 
Variables (%, median/IQR) Overall 
N=320 
Lowest/improving 
n=197 
Elevated/stable 
n=108 
Elevated/ 
worsening 
n=15 
p-value 
Treatment group, no (%)     0.29 
    Usual care 157 (49) 92 (47) 55 (51) 10 (67)  
    Exercise training 163 (51) 105 (53) 53 (49) 5 (33)  
Age, median (IQR)    58 (51, 67) 59 (51, 69) 57 (52, 65) 57 (43, 64) 0.15 
Female sex (%) 86 (27) 48 (24) 36 (33) 2 (13) 0.12 
Race n=315 (%)     0.76 
     Black or Other 112 (36) 66 (34) 41 (38) 5 (33)  
     White 203 (64) 127 (66) 66 (62) 10 (67)  
New York Heart Association class (%)     0.15 
     II 226 (71) 145 (74) 69 (64) 12 (80)  
     III/IV 94 (29) 52 (26) 39 (36) 3 (20)  
Ischemic etiology of heart  
failure (%) 
167 (52) 96 (49) 63 (58) 8 (53) 0.27 
Diabetes mellitus (%) 108 (34) 69 (35) 33 (31) 6 (40) 0.64 
Previous Myocardial Infarction (%) 126 (39) 80 (41) 40 (37) 6 (40) 0.83 
Hypertension (%) 194 (60) 113 (57) 74 (69) 7 (47) 0.09 
Atrial fibrillation or atrial flutter (%) 64 (20) 36 (18) 23 (21) 5 (33) 0.34 
Clinical values, median (IQR)      
Left ventricular ejection fraction  24 (21, 30) 25 (21, 30) 25 (20, 30) 24 (18, 29) 0.50 
Systolic blood pressure,  
mm Hg 
112  
(102, 130) 
113  
(102, 130) 
110  
(99, 130) 
112  
(100, 122) 
0.71 
Diastolic blood pressure, mm Hg 70  (61, 80)  70 (60, 80) 70 (62, 78) 68 (60, 74) 0.81 
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Sodium at baseline, mEq/L 139 (138,141) 140 (138, 141) 139 (138, 141)     139 (136, 140) 0.33 
Creatinine at baseline, mg/dL, n=294 1.2 (1.0, 1.5) 1.1 (1.0, 1.4) 1.2 (1.0, 1.5) 1.2 (0.9, 1.6) 0.13 
BUN, mg/dL, n=292 20 (15, 27) 19 (15, 25) 22 (15, 31) 22 (15, 27) 0.23 
Beck Depression Index II, n=318 8 (4, 15) 7 (4, 15) 8 (4, 15) 13 (5, 7) 0.16 
Baseline use of medications and 
devices (%) 
     
ACE inhibitor or ARB 305 (95) 189 (96) 102 (94) 14 (93) 0.78 
B-blocker  299 (93) 183 (93) 101 (94) 15 (100) 0.56 
Loop diuretic  241 (75) 135 (69) 94 (87) 12 (80) 0.001* 
Statin 156 (49) 98 (50) 50 (46) 8 (53) 0.79 
Implantable cardioverter-
defibrillator  
118 (37) 63 (32) 48 (44) 7 (47) 0.07 
Pacer 61 (19) 33 (17) 24 (22) 4 (27) 0.39 
Biventricular pacemaker  44 (14) 20 (10) 20 (19) 4 (27) 0.042* 
Functional measures (median, 
IQR) 
     
Peak oxygen consumption, 
mL/kg/min  
15.2  
(12.2, 17.8) 
15.6  
(13.1, 18.2) 
13.4  
(11.3, 16.9) 
14.5  
(12.8, 16.9) 
0.002* 
Body mass index, kg/m2,  30 (26, 35)   29 (25, 33) 32 (28, 38) 20 (26, 35) <0.001* 
Six minute walk test, m (n=312) 384.0  
(314.9, 440.2) 
384.8  
(320.0, 441.9) 
384.0  
(306.6, 438.9) 
356.0  
(306.0, 423.7) 
0.40 
EuroQol-5D (%)       
Question 4: Pain/Discomfort (n=317)     0.22 
     No pain or discomfort 149 (47) 102 (52) 41 (39) 6 (40)  
     Moderate pain 161 (51) 90 (46) 62 (59) 9 (60)  
     Extreme pain 7 (2.2) 4 (2.0) 3 (28) 0 (0)  
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Question 5: Anxiety (n=318)     0.54 
    Not anxious 187 (59) 118 (61) 62 (57) 7 (47)  
    Moderately/Extremely 
anxious 
131 (41) 77 (39) 46 (43) 8 (53)  
Data are complete for all 320 participants unless otherwise indicated, p-values indicate difference in mean values across biomarker 
subgroups for continuous variables. Abbreviations: IQR: interquartile range; BUN: blood urea nitrogen; ACE: angiotensin-converting-
enzyme; ARB: angiotensin II receptor blocker  *p-values are significant (<0.05) between the biomarker patterns
  84 
Baseline socio-demographic and clinical characteristics were compared 
between the original parent cohort and this subgroup. In general, the subpopulation 
was representative of the parent cohort, but there were significant differences in the 
proportions of patients in NYHA class II at baseline in the sample versus total 
population (71% versus 63%, p=0.008). There were no statistically significant 
differences between the means in the usual care and intervention groups for ln(NT-
proBNP) between baseline and 3 months (p=0.499) or baseline and 12 months 
(p=0.471). There were also no differences in ln(hsCRP) from baseline to 3 months 
(p=0.168) or baseline to 12 months (p=0.193) between the usual care and intervention 
groups (Figure 4.2). Thus, growth mixture modeling was used to further identify and 
describe potential underlying patterns.  
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Figure 4.2 HsCRP and NT-proBNP for exercise training and usual care groups  
                        
Identification of Multiple Patterns of Change in Biomarkers Over Time  
Three statistically independent and clinically meaningful biomarker patterns of 
NTproBNP and hsCRP were identified (model entropy: 0.79, Lo-Mendell Rubin test p-
value=0.016) (Figure 4.3). Based on the observed characteristics of NT-proBNP and 
hsCRP, the first pattern of change (n=197 [61%]; average posterior probability = 0.923) 
was labeled “lowest/ improving.” That is, patients classified in the lowest/improving 
pattern had the lowest levels of NT-proBNP and hsCRP at baseline, and there were 
significant declines in both NT-proBNP (p=0.006) and hsCRP (p<0.001) over the course 
of 12-months. The second pattern of change (n=108 [34%]; average posterior probability 
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= 0.872) was labeled “elevated/stable.” Patients classified in the elevated/stable pattern 
had higher hsCRP (p<0.001) and similar NT-proBNP levels (p=0.885) compared with the 
lowest/improving pattern at baseline. In the elevated/stable pattern, there were slight 
improvements in hsCRP over the 12-month follow-up period (p=0.017). The third and 
smallest pattern of change (n=15 [5%]; average posterior probability was 0.900) was 
labeled “elevated/worsening” because patients fitting this pattern had the highest levels 
of NT-proBNP at baseline that did not change over time (p=0.827), and hsCRP increased 
significantly over 12 months (p<0.001). 
Figure 4.3 Bio-marker patterns   
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Identification of Biomarker Pattern Determinants 
Determinants of the elevated/stable and elevated/worsening biomarker patterns 
from the multinomial regression are presented in Table 4.3, (model χ2=90.71, p<0.001, 
pseudo R2=19.51%). Participants randomized to the exercise therapy intervention were 
77% less likely (RRR: 0.23, p=0.037) to be in the elevated/worsening compared to 
lowest/improving pattern. The risk of being in the elevated/worsening pattern was also 
almost six times higher (RRR: 5.84, p=0.033) for participants who had a bi-ventricular 
pacemaker prior to baseline, and over 1.5 times (RRR: 1.68, p=0.005) higher for each 
unit increase in serum creatinine at baseline. The absolute difference in mean creatinine 
at baseline was 0.5 higher in the elevated/worsening compared to the lowest/improving 
pattern. 
Table 4.3: Multinomial regression model predicting elevated/stable and 
elevated/worsening patterns of change 
 
Variable Relative Risk 
Ratio 
95% 
Confidence 
Interval 
p-value 
*Predictors of the elevated/stable pattern 
  Exercise group 0.53 0.29-0.99 0.045 
  Loop diuretics 3.00 1.29-7.00 0.010 
  Hypertension 2.52 1.28-4.96 0.008 
  Ischemic etiology 2.22 1.08-4.51 0.028 
  Pain 1.80 0.99-3.26 0.054 
  Body mass index, kg/m2 1.08 1.02-1.13 0.005 
  Peak Vo2, mL/kg/min 0.92 0.85-1.00 0.057 
  Diabetes 0.44 0.23-0.86 0.017 
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†Predictors of the elevated/worsening pattern 
   Exercise group 0.23 0.06-0.92 0.037 
   Bi-ventricular pacer 5.84 1.16- 29.5 0.033 
   Baseline creatinine 1.68 1.17-2.42 0.005 
* These results compare the elevated/stable to lowest/improving pattern  
† These results compare the elevated/worsening to lowest/improving pattern 
 
 
Participants in the exercise intervention group were 47% less likely (RRR: 0.53, 
p=0.045) to be in the elevated/stable compared to lowest/improving biomarker pattern. 
Participants with diabetes were also less likely to be in the elevated/stable pattern 
(p=0.017). Participants who were taking a loop diuretic had three times the risk (RRR: 
3.0, p=0.010) of being in the elevated/stable, compared to lowest and improving pattern. 
Likewise, participants had over double the risk of being in the elevated/stable pattern if 
they had hypertension (RRR: 2.52, p=0.008) or heart failure of ischemic etiology (RRR: 
2.22, p=0.028). Each additional unit of BMI was associated with an 8% increase (RRR: 
1.08, p=0.005) in the likelihood of being in the elevated/stable pattern.  
 The results of the logistic model, which combined the elevated/stable and 
elevated/worsening and compared them with the lowest/improving pattern, were 
consistent with the multinomial results (Table 4.4). Once again, being in the exercise 
group provided a 51% protective effect (OR: 0.49, p=0.018) compared to the usual care 
group for not being in the combined elevated/worsening pattern. Consistent with the 
previous model, participants with diabetes were less likely to be associated with the 
worse biomarker pattern (p=0.026). The odds of being in the combined 
elevated/worsening pattern were over two times higher for patients with heart failure of 
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ischemic etiology (OR: 2.13, p=0.030), hypertension (RR: 2.05, p=0.028) or for those on 
loop diuretics (OR: 2.38, p=0.026). The odds of being in the combined 
elevated/worsening pattern were also 8% higher for each unit increase in BMI (OR: 1.08, 
p=0.003). The variables in the model offer fair prognostication for the combined 
elevated/worsening pattern (area under the curve: 0.78).
 
 
 
Discussion  
 
Using the growth mixture modeling, we identified a deleterious biomarker pattern 
characterized by elevated myocardial stress and inflammation and a favorable pattern 
characterized by lower myocardial stress and decreasing inflammation over 12-months. 
Exercise therapy was protective for not having the elevated/worsening pattern of change 
in biomarkers over time. This finding supports the potential for exercise therapy to 
contribute to slowing or preventing the progression of heart failure.31  
Table 4.4: Predictors of the combined elevated/worsening compared to 
lowest/improving pattern 
Variable Odds Ratio 95% Confidence Interval p-value 
   Exercise group 0.49 0.27-0.89 0.018 
   Ischemic etiology 2.13 1.08-4.24 0.030 
   Loop diuretic 2.38 1.11-5.11 0.026 
   Hypertension 2.05 1.08-3.89 0.028 
   Body mass index 1.08 1.03-1.13 0.003 
   Diabetes 0.48 0.25-0.91 0.026 
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The finding that there are no mean differences in mean ln(NT-proBNP) or 
ln(hsCRP) over time between the exercise and usual care group are consistent with the 
study by Ahmad and colleagues that used a sample of 928 participants from the HF-
ACTION study.22 Ahmad and colleagues reported that exercise training (measured by 
volume of exercise) was not associated with numerical decreases in NT-proBNP and 
hsCRP from baseline to 3-months.22 In an effort to further explain the relationship 
between these biomarkers (NT-proBNP and hsCRP) and exercise therapy, this study used 
growth mixture modeling to identify distinct multi-marker biomarker patterns. This 
methodology is especially relevant for a heterogeneous heart failure population, where 
being able to identify distinct sub-groups (or patterns) is clinically informative.  When 
NT-proBNP and hsCRP were combined into distinct multi-marker patterns, we identified 
an elevated/worsening pattern with rising hsCRP over 12-months. The characteristics of 
this pattern may partially explain why there was not a statistically significant mean 
reduction in hsCRP in the exercise therapy group compared to usual care. The study 
findings reported here are consistent with results from the Cardiovascular Health Study 
(CHS), in which deFilippi and colleagues reported a protective effect of moderate 
physical activity on the risk of developing heart failure, neurohormonal activation 
(measured by NT-proBNP) and cardiac injury (measured by Troponin T).32  
One predictor of the elevated/worsening pattern of change was having a bi-
ventricular pacemaker. More participants with a bi-ventricular pacer were also classified 
as NYHA III/IV, indicating that having a bi-ventricular pacer may be a proxy for heart 
failure severity. Higher baseline creatinine was also associated with over a one-and-a-half 
fold risk of having the elevated/worsening pattern. Worsening renal function is defined as 
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absolute creatinine elevation of 0.1 to 0.5 mg/dL.33 The difference between the 
lowest/improving and elevated/worsening was 0.5 mg/dL, which is a clinically 
meaningful difference because of the association with 6-month mortality, readmission 
and functional decline.33 This finding is consistent the Breathing Not Properly study 
where there was a weak but significant correlation between estimated glomerular 
filtration rate (eGFR) and BNP.34 Likewise, in a study reported by Anwaruddin and 
colleagues, lower eGFR was associated with higher proBNP.35 The relationship between 
renal function and natriuretic peptides is complex and may be explained by elevated 
intravascular volume, atrial pressure, systemic pressure or by ventricular mass.36 
When comparing the elevated/stable pattern, in which there was an elevation in 
hsCRP, but not NT-proBNP, with the lowest/improving pattern, once again, participants 
randomized to the exercise therapy intervention were much less likely to have the 
deleterious biomarker pattern. Hypertension was associated with a two and a half fold 
risk of being in the elevated/stable compared to lowest/improving pattern, along with 
other measures of severity—being on a loop diuretic or having heart failure of ischemic 
etiology. Many patients with reduced renal function also have hypertension, which can 
cause left ventricular hypertrophy and elevated natriuretic peptides.36 Hypertension and 
hsCRP have also been associated in other studies due to shared mechanisms of oxidative 
stress and endothelial dysfunction.37 Specifically, hsCRP is known to attenuate nitric 
oxide production and decrease endothelial nitric oxide synthase expression leading to 
vasoconstriction and atherothrombosis.20 The association between elevated hsCRP and 
hypertension is consistent across multiple racial and ethnic groups.38,39  
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Higher BMI was also associated with the elevated/stable biomarker pattern. The 
inverse relationship between BMI and NT-proBNP has been reported in many other 
studies,40-44 explaining why obesity was associated with the elevated/stable and not the 
most unfavorable pattern—elevated/worsening. One theory for this inverse association is 
that there is increased clearance of NT-proBNP by type C natriuretic peptide receptors on 
adipocytes.45 In obese patients, natriuretic peptides are still routinely used for diagnostic 
purposes, but at lower cutoff levels.43  
Diabetes was also associated with a 56% lower risk of being in the elevated/stable 
compared to lowest/improving biomarker pattern. This may be explained by a higher 
proportion of diabetic patients being on a statin medication compared to non-diabetics 
(59% versus 43%). Statins are associated with reduced hsCRP in diabetic patients.46 The 
apparently protective effect of diabetes may be due to chance, or it might be related to the 
fact that diabetic participants were less likely than non-diabetic participants to have 
ischemic etiology (44% versus 56%).  However, controlling for statin use and ischemic 
vs. non-ischemic etiology in post-hoc models did not change the strength of the 
relationship between diabetes and the risk of having the hazardous patterns of change in 
these biomarkers. More research is needed to further explore associations among diabetes 
and other comorbidities in heart failure and the systemic inflammatory and myocardial 
stress responses to exercise.  
Strengths and Limitations 
The growth mixture modeling analytic approach was a major strength of this 
study because it allowed for the identification of previously unobserved biomarker 
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patterns of change. As such, it is a useful analytic tool for helping to explain the 
heterogeneity in response to exercise therapy that is common among patients with heart 
failure. Another strength of this study was that it built off the results of the Ahmad 
study,22 demonstrating how different types of biomarker analyses can help to explain how 
exercise may be able to slow or prevent the progression of heart failure.31 
One potential limitation of this study is its generalizability because it was 
conducted on a random sample of the biomarker sub-study with near-complete data. This 
random sample is representative of the larger HF-ACTION trial population. Though it is 
unlikely that our results were solely a function of sample selection, it is possible that if 
this analysis were done on in the entire dataset that the results would be different. The 
relative risk reduction reported in this study should be interpreted with caution because 
the elevated/worsening pattern was relatively small and the overall sample size of the 
study was modest. Although we successfully identified statistically distinct biomarker 
subgroups and corresponding predictors, further testing in a larger sample may increase 
the precision of the estimates. Given that the measure of exercise was randomization to 
the exercise intervention, rather than quantity, it is likely that the protective effect of 
exercise would be stronger if adherence were accounted for. The final limitation is that 
the exercise therapy group tended to have lower NT-proBNP at baseline, though this 
difference was not statistically significant (p=0.083). This slight imbalance at 
randomization is unlikely to account for the protective effect of exercise therapy reported 
in this study.  
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In summary, these study results indicate that exercise therapy may prevent 
worsening inflammation and myocardial stress in patients with stable heart failure and 
help counteract the pathophysiological processes of the heart failure progression through 
multiple biologic mechanisms. These results contribute to the body of knowledge on 
exercise as a preventative and therapeutic intervention for patients with heart failure.  
There are many related avenues for future research around exercise and heart 
failure, including further elucidation of mechanisms of benefit, identifying which 
biomarkers are modified by exercise, quantifying the dose of exercise needed to achieve a 
benefit, and identifying ways to engage heart failure patients in exercise.31 There is also a 
strong need to identify different exercise regimens for patients with heart failure and 
prevalent comorbid conditions such as type 2 diabetes. In the future, multi-marker 
biomarker analyses of exercise interventions may also be able to clarify which patients 
can be expected to benefit from exercise by demonstrating the mechanism by which 
exercise slows the progression of heart failure.31 
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Abstract 
 
Lack of engagement in self-care is common among patients needing to follow a 
complex treatment regimen, especially patients with heart failure who are affected by 
comorbidity, disability, and the side effects of poly-pharmacy. In response, clinical 
practice guidelines recommend using behavioral approaches to engage patients in self-
care. The efficacy of motivational interviewing to improve self-care in patients with heart 
failure remains understudied. We are conducting a brief, nurse-led motivational 
interviewing randomized controlled trial to address behavioral and motivational issues 
related to heart failure self-care. Participants who are randomized to the intervention 
group receive both home and phone-based motivational interviewing sessions over 90 
days. Participants in the control group receive care as usual. The purpose of the study is 
to test the efficacy of a MI intervention on self-care, physical HF symptoms and quality 
of life. This article presents the study design and methods and plans for statistical 
analysis for Motivational Interviewing Tailored Interventions for Heart Failure (MITI-
HF). Study findings will contribute to the literature on the efficacy of motivational 
interviewing to promote heart failure self-care.  
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Introduction  
 
Heart failure is a cardiovascular syndrome affecting more than 5.1 million 
Americans. It is growing in prevalence with 670,000 new cases diagnosed each year,1 
especially among patients older than 80 years.2 The management of heart failure is 
complex because it often occurs in the context of multiple comorbid conditions.2 Each 
comorbid condition requires specific self-care, making prioritization a persistent 
challenge. One method that has been efficacious for decreasing symptom prevalence and 
preventing re-hospitalization is the promotion of self-care.3 Initiating effective self-care 
for early signs and symptoms of heart failure may help patients have a better quality of 
life3 and delay the onset of an acute decompensation.4,5 
Self-care for patients with heart failure has been defined as a naturalistic decision-
making process comprised of both self-care maintenance and self-care management.6,7 
Self-care maintenance involves choosing positive health practices that may help to 
prevent an acute exacerbation (e.g. taking medication as prescribed, consuming a low-salt 
diet, staying physically active, and monitoring daily weight). Self-care management 
builds on these routine behaviors and includes critical decision-making and follow-up 
actions around managing signs and symptoms when they occur (e.g., taking an extra 
diuretic for shortness of breath).6-8 Heart failure self-care must be adapted to the 
individual because each person has his or her own symptom experience and functional 
disability.  
Early evidence from a mixed-methods pilot study9 suggested that a motivational 
interviewing (MI) intervention was beneficial for adults with heart failure by improving 
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their self-care.9 Riegel and colleagues reported that the effectiveness of the intervention 
was due to the MI approach.9 Building upon these earlier findings, MITI-HF was 
designed improve heart failure self-care maintenance behaviors using MI.  
The article describes the study design and research methods used to evaluate the 
intervention (Clinicaltrials.gov ID MITI-HF_EGKMF). We designed Motivational 
Interviewing Tailored Interventions for Heart Failure (MITI-HF) to examine the 
feasibility and efficacy of a MI intervention to improve patients’ self-care. The primary 
aim of the study is to test the feasibility and preliminary efficacy of MITI-HF for its 
impacts on heart failure self-care over 90 days.  The secondary aim is to examine the 
impact of MITI-HF on secondary outcomes of physical HF symptoms and quality of life 
over 90 days.  
Background 
To improve self-care, this study uses a tailored MI approach. Traditionally, 
patient education programs focus on disseminating didactic information. Information 
alone is rarely sufficient to influence symptom management behaviors,10-12 especially in 
the case of heart failure where there are often competing co-morbidities including 
diabetes mellitus (38%), hypertension (73%), kidney disease (45.9%) and obesity 
(46.8%),2 in addition to chronic obstructive pulmonary disease, depression, and cognitive 
impairment.13-15 Overall, educational approaches for improving heart failure self-care 
have been developed and tested with little impact on heart failure outcomes.16-18   
Tailored interventions are designed to address the individual characteristics of 
persons within a sample.19 Conceptually, this is similar to the Lauver et al definition of 
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individual-centered interventions, which addresses either characteristics and experiences 
or individuals’ goals or preferences.20 In this case, the intervention is targeted to 
hospitalized patients with chronic heart failure and then tailored specifically to patient’s 
goals and to match individuals’ unique self-care maintenance or management needs. We 
postulated that a tailored MI approach would help patients with heart failure address 
behaviors that are problematic by increasing internal motivation to engage in specific 
self-care behaviors chosen by the patient.  
MI is grounded in client-centered counseling, cognitive-behavioral therapy, and 
social cognitive therapy.21 MI also incorporates the Transtheoretical Model of Behavior 
Change, which assesses a patient’s readiness to change behavior and develops strategies 
to move toward taking action to change behavior.22 MI integrates the concepts of 
relationship building from humanistic therapy23 with active strategies oriented towards 
stages of change.22 The main characteristics of motivational interviewing are: expressing 
empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy.24  
The interviewer maintains a nonjudgmental approach and allows the patient to determine 
the need for behavioral change, rather than offering unsolicited advice on the need for 
change. The interviewer only explores ways to implement change once the patient 
expresses the desire and confidence to change. The goal of MI is to help individuals work 
through inherent ambivalence present in problematic or unhealthy behaviors,24,25 and to 
help them verbally express their own reasons for or against change using a 
nonjudgmental, empathetic and encouraging tone.26 MI can help people identify how 
their current behaviors conflict with their ability to achieve personal health goals, 
especially in the context of low readiness to change.26  
  103 
MI was initially developed for the treatment of substance abuse.27-29 Due to its 
strong theoretical base and empirical support, MI is now used for patients with a wide 
variety of unhealthy behaviors including illicit drug abuse, eating disorders, asthma, HIV 
risk behavior, and gambling.30 It is also used for cardiovascular diseases, including heart 
failure in acute and outpatient settings.9,31-33 Brodie and colleagues used MI to increase 
physical activity among older adults with heart failure,31 as well as general and disease 
specific quality of life.32 MI has specifically been used to improve heart failure self-care 
in small pilot studies;9,34 however, larger studies are needed to build the body of evidence 
and confirm the preliminary albeit promising results of these small pilot trials.  
Theoretical Frameworks 
The Situation Specific Theory of Heart Failure Self-care6 is used as the guiding 
theoretical framework for the study. The Model for Tailoring Behavioral Interventions19 
was used to plan, implement and evaluate the tailored intervention, and MI is the 
mechanism for delivery.   
Intervention development 
The Model for Tailoring Behavioral Interventions19 was used to develop and test 
the tailored intervention. The Model for Tailoring Behavioral Interventions has five steps: 
1) understanding, 2) assessing, 3) planning, 4) implementing and 5) evaluating. The first 
step in designing the tailored intervention was selecting the individual characteristics on 
which the intervention would be tailored.19 In this study tailoring was based on physical, 
mental, and behavioral health characteristics. Physically, all participants in the study have 
had a recent hospitalization for acute decompensation of heart failure. Behavioral 
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decision-making is at the heart of self-care so participants’ self-care scores were assessed 
using the Self-Care of Heart Failure Index (SCHFI) v 6.2.7,35 The intervention was 
planned based on areas that patients were deficient in according to the SCHFI as well as 
their self-defined goals. For example, if a patient’s goal was: “to be able to attend my 
grandson’s football games this fall,” the nurse tailors the intervention to specific physical 
activity needs. Implementation includes conducting a randomized controlled trial. The 
study outcomes are common across individuals despite the fact that each intervention is 
tailored to participants’ unique goals and areas that they self-defined as needing growth.  
Usual care 
All participants are enrolled from the hospital and both the intervention and the 
control groups receive patient education materials in the hospital. Patient education sheets 
were designed by Krames StayWell for a 6th grade or below literacy level, according to 
the Fog Index (Table 5.1).36 The photographic images in the materials are commensurate 
with the demographics and culture of the study population. For instance, the “Busting 
Barriers” sheet pictures three generations of African American males to reinforce the 
benefits of social and familial support. All of the educational sheets targeted goal 
behavior changes through participant interaction, such as writing down the names of 
support people who would help them see habits that might block their progress toward 
change. Individuals randomized to the UC did not receive any other intervention.  
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Table 5.1 Patient Education Materials  
Patient Education Sheet Educational content areas 
Busting Self-Care Barriers 
Helps patients to identify possible challenges to self-care 
in order to prevent them from becoming barriers; 
recommendations include being active, reducing salt, 
limiting fluid, taking an extra water pill, and calling a 
healthcare provider. 
Breaking Down Your 
Barriers 
 
Describes how to take steps to improve self-care, identify 
support people, and identify benefits of self-care 
behaviors.  
Dealing with Heart Failure 
Symptoms 
 
Helps patients record baseline information such as weight, 
walking distance, and amount of stairs able to climb 
before becoming short of breath.  
Watch for Changes 
 
After baseline information has been identified, this is a 
worksheet describes how to monitor symptom changes. It 
also offers tips for limiting salt and fluids. 
Stay Active to Help Your 
Heart 
 
Focuses on how to incorporate activity into a daily 
routine, including how to choose an activity and warning 
signs of overexertion. 
Adding Activity to Your 
Day 
 
Includes tips for making activity part of your day, and for 
how to keep it fun by walking with friends or reading a 
book while on an exercise bike. 
My Heart Failure 
Symptom Chart 
 
This chart is for recording daily weight, change from 
baseline weight and changes in symptoms. 
My Symptom Action Plan 
 
This worksheet is for recording action plans for different 
scenarios of worsening heart failure symptoms, including 
swelling, increased shortness of breath, and weight gain of 
2 or more pounds in 1 day. 
 
Motivational Interviewing Intervention 
 Heart failure specialist nurses provide the MI intervention. The nurses conduct 
one home-based MI intervention session followed up by three MI phone calls over 90 
days. The intervention begins with a conversation about the participant’s self-identified 
goals. During the home intervention, the nurses focus on self-care areas that the 
  106 
participant identifies as high priority. During that visit the participant sets specific goals, 
which the nurses follow up with and reinforce over the follow-up phone calls. Based on 
our prior work with motivational interviewing, we anticipate that one 60-minute session 
and three to four follow-up phone calls scheduled over the following few months are 
adequate to deliver this intervention.9  
Interventionist Training 
Before starting the study, the bachelor or masters degree prepared nurse 
interventionists received two full days of training covering detailed aspects of MI theory 
and heart failure-specific self-care techniques and skills. The principal investigators and 
an expert in MI supervised both training days. The nurses practiced the techniques of MI 
through numerous role-play scenarios with one another and the facilitators.  
Treatment Fidelity 
Treatment fidelity is monitored throughout the intervention by recording all of the 
intervention sessions. All audiotaped intervention sessions are transcribed, and analyzed 
to assess treatment fidelity, a methodological strategy used to monitor and enhance the 
reliability and validity of the intervention.37 Prior to implementation of the protocol, a 
standardized rubric was developed based on the intervention manual to score adherence 
to the study protocol including the use of the principles of MI. This provided a 
mechanism for providing corrective feedback to the interventionists regarding deviations 
from the study protocol. Each audio recording is reviewed to determine the proportion of 
the intervention elements covered by the nurse interventionist using a checklist. In 
addition to ongoing feedback with the interventionists, a psychologist trained in MI also 
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reviews random transcripts and provides feedback to the interventionists on the quality of 
MI as well as adherence to the protocol.  
Study Design  
 
MITI-HF is a prospective, single blinded, pilot feasibility randomized single-site 
trial. The target sample size is 65 participants; however, to account for an estimated 35% 
attrition rate, the target number for recruitment is 100 participants. The target sample size 
was calculated based on a 2:1 randomization scheme (intervention: control) with 90% 
power (5% alpha) to detect a difference of 80% versus 50% (intervention and control 
group) of scoring over 70 on the SCHFI, which is the cut-off for adequate self-care35 at 
three months. The power analysis was performed using G*Power 38 and confirmed with 
PASS.39 
Procedures 
 
To achieve balance in the study arms, randomization is performed using 
minimization,40 stratifying participants on NYHA class and gender. Randomization to the 
intervention or usual care group occurs after the informed consent form is signed and a 
cardiologist scored New York Heart Association (NYHA) Functional Class interview 
(Figure 5.1). 
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Figure 5.1: MITI-HF flow chart 
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Data Collection 
Medical history, including comorbidities and heart failure characteristics, are 
obtained from patients’ electronic medical records. Kansas City Cardiomyopathy 
Questionnaire (KCCQ) and Heart Failure Somatic Perception Scale (HFSPS) data are 
collected at baseline approximately two weeks after hospital discharge via phone call by 
research assistants blinded to study group. Over time, we realized that the 6-item 
screening tool for cognition was not adequate to pick up some cases of severe cognitive 
impairment. In response, a second screening was put in place two weeks after discharge 
and before the baseline questionnaires were completed. If participants had no recollection 
of the study, or signing the informed consent during the baseline call, they were excluded 
from the study on the grounds that they had cognitive impairment severe enough to meet 
exclusion criteria. Research assistants collect follow-up data at 90 days on the SCHFI, 
KCCQ, HFSPS and self-reported clinical events.  
Sample 
Adults with heart failure are enrolled into the MITI-HF study from two urban 
inpatient cardiology units. To be included, participants have to: 1) be hospitalized with a 
primary or secondary diagnosis of heart failure, 2) be able to read and speak English, 3) 
be 18 years of age or older 4) live in a setting where they can independently engage in 
self-care, 5) live within 30 miles from the university hospital 6) have at least adequate 
health literacy, 7) have symptomatic HF  (NYHA II-IV) and 8) be willing to participate. 
Exclusion criteria included: 1) being on a Milrinone drip, 2) being on a list for an 
implanted ventricular assist device or heart transplant, 3) pregnancy, 4) psychosis and 5) 
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cognitive impairment with the inability to participate in the intervention or complete the 
study instruments. Study enrollment took place from January 2012 to December 2013. 
Ethics 
The institutional review board at the affiliated University approved the study 
protocol. Written informed consent and Health Insurance Portability and Accountability 
Act authorization are obtained from all interested participants. All research assistants are 
trained in HIPAA confidentiality and the protection of human research subjects.  All 
procedures are in accordance with the Declaration of Helsinki.41  
Measurement of Variables 
 
Self-care is measured using the SCHFI v. 6.2, a 22-item, interviewer-administered 
instrument that quantifies HF patients’ self- care maintenance, self-care management, and 
self-care confidence (self-efficacy).7,35 Each scale score ranges from 0 to 100; higher 
scores indicate better self-care. Quality of life is measured with the KCCQ, which has 23 
items that can be quantified into five subscales: physical limitations, symptoms, quality 
of life, social interference, and self-efficacy. Each domain-specific subscale and the 
overall clinical summary score range from 0 to 100.42 Higher scores indicate better 
quality of life. Acute physical symptom recognition is measured with the HFSPS. Scores 
are calculated by summing responses; higher values reflect worse physical symptom 
distress.  
Data Analyses 
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Standard descriptive statistics of frequency, central tendency, and dispersion will 
be used to describe all measures of the study at baseline. Comparisons of socio 
demographic and clinical characteristics between the intervention and usual care groups 
at baseline will be reported using Student’s t, Pearson χ2 analysis or ANOVA where 
appropriate. Differences between groups in improvements in self-care will be quantified 
using t-tests without assuming equal variance; Cohen’s d is calculated as a standardized 
index of effect size. Repeated measures tests are used within subjects. Analyses will be 
conducted using StataSE (College Station, Texas) using intention-to-treat. Effect sizes 
will be calculated with G Power. 38 
Conclusion 
 
This article describes the development and implementation of MITI-HF, a tailored 
MI intervention to support heart failure self-care. The significance of this study is that it 
tests an innovative, MI intervention that has high potential to be integrated into 
transitional care discharge planning services. We anticipate that using this MI approach 
can help patients with heart failure focus on their internal motivation to change in a non-
confrontational, patient-centered, collaborative way. It also affirms their ability to 
practice competent self-care relevant to their personal health goals. Future articles will 
present the results of the study and implications for heart failure research and clinical 
practice. 
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Abstract 
 
Background: Self-care has been shown to decrease symptom prevalence, improve 
quality of life, delay the onset of acute decompensation and prevent hospitalization for 
patients with heart failure (HF). The efficacy of using motivational interviewing (MI) to 
improve self-care is unknown.  
Methods and Results: We conducted a randomized controlled trial to test the 
comparative efficacy of a tailored MI intervention versus usual care in improving HF 
self-care behaviors, physical HF symptoms and quality of life. The intervention consisted 
of a single home visit and 3-4 follow-up phone calls by a nurse over 90 days. A total of 
67 participants completed the study (mean age 62 ± 12.8 years), of which 54% were 
Black, 30% were female, 84% had class III/IV symptoms, and 63% were educated at a 
high school level or less. Both the intervention and usual care groups had significant 
improvements in self-care maintenance and confidence (all p<0.01); the intervention 
group also had a significant improvement in self-care management (p<0.01). However, 
participants in the intervention group had a 9-point greater improvement in self-care 
maintenance compared with the usual care group (p=0.026) at 90 days. There were no 
differences between the groups in self-care management, confidence, physical HF 
symptoms or quality of life at 90 days.  
Conclusions: Patients with HF who received the MI intervention had statistically 
significant and clinically meaningful improvements in self-care maintenance over 90 
days that exceeded that of usual care. Overall, MI is an effective approach for improving 
self-care maintenance.  
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Introduction 
 
Heart failure (HF) affects more than 5.1 million Americans1 and costs the United 
States $39.2 billion annually.2 HF is currently the most common reason for the 
hospitalization of Medicare recipients.3-6 The costs for preventable readmissions are 
estimated to be about $17 billion or 20% of Medicare’s hospital payments.7 Patients with 
HF are frequently admitted to the hospital because they experience exacerbations in 
symptoms with fluid retention, shortness of breath, and fatigue on exertion.8 Considering 
the increasing prevalence, cost and social burden to patients and their families, 
interventions that incorporate self-care with effective medical therapy are critical to 
optimize patient health and improve patient outcomes.9-11  
Self-care has the potential to reduce hospitalizations and improve quality of life. 
Several studies have examined the impact of self-care education on patient-oriented and 
clinical outcomes including self-care behaviors,12 self-efficacy,13 quality of life,13-16 
physical activity,17 health status,18 hospitalizations,19,20 mortality,16 myocardial stress,21 
and systemic inflammation.22 Overall, there has been an apparent lack of effectiveness of 
self-care education on clinical outcomes. One reason is that patients face a number of 
prohibitive barriers to mastering self-care skills and knowledge, including cognitive 
impairment, excessive daytime sleepiness, low-health literacy,23-25 and poor motivation.26 
Motivational interviewing (MI) has been proposed as a client-centered strategy to engage 
patients in self-care,12,27 and improve self-efficacy and readiness to change.  
The purpose of this randomized controlled trial (Motivational Interviewing 
Tailored Interventions for Heart Failure [MITI-HF]) was to test a tailored MI intervention 
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designed to improve self-care compared to usual care. The primary study outcome was 
change in self-care maintenance (i.e. daily behaviors like taking prescribed medications, 
restricting fluid and dietary sodium intake, participating in health-seeking behaviors, and 
monitoring for HF symptoms). The main hypothesis was that HF patients enrolled in the 
group receiving a uniquely tailored MI intervention would improve in self-care after 90 
days. Secondary outcomes included physical HF symptoms and quality of life.  
Methods 
 
Study design 
 MITI-HF was a prospective, single-blinded, pilot randomized controlled trial. The 
University’s Institutional Review Board approved the study, which actively enrolled 
participants from January 2012 to December 2013. Detailed description of study methods 
including participant eligibility, recruitment procedures and data collection have been 
registered (Clinicaltrials.gov MITI-HF_EGKMF), reported in a study design paper28 and 
are summarized here. The target recruitment size was 100 participants, a sample size 
calculated to provide 90% power (5% alpha) to detect a difference of 80% versus 50% 
(intervention and control group) likelihood of scoring over 70 on the Self-Care of Heart 
Failure Index (SCHFI) v.6.2 at 90 days. The power analysis was performed using 
G*Power 29 and confirmed with PASS.30 
Participants 
One hundred participants were randomized to receive the MITI-HF intervention 
or usual care after a HF-related hospitalization. The study inclusion and exclusion criteria 
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are shown in Table 6.1. Potential participants were approached during an inpatient HF-
related hospitalization at a University affiliated urban hospital. All eligible patients were 
screened for health literacy,31 cognitive impairment (using a six-item screener derived 
from the Mini Mental Status Exam (MMSE)),32 baseline self-care (using the SCHFI 
v.6.2),33 and a standardized interview to assess New York Heart Association (NYHA) 
functional class.34 Those who met the inclusion criteria and agreed to participate provided 
written informed consent. At the end of this visit, all participants received a set of 
educational fliers related to identifying and addressing self-care barriers, dealing with 
heart failure symptoms, maintaining a lower sodium diet and an active lifestyle. 
Participants were then randomized by minimization35 to one of two intervention groups 
with a 2:1 randomization ratio stratified by NYHA functional class and gender.36 
Table 6.1. Eligibility Criteria  
Inclusion Criteria Exclusion Criteria 
1. Hospitalized with a primary or secondary 
diagnosis of HF 
1. Current treatment with milrinone 
2. Able to read and speak English  2. On a list for an implanted VAD or heart 
transplant 
3. 18 years of age or older  3. Pregnancy 
4. Living in a setting to independently engage 
in self-care 
4. Psychosis 
5. Living within 30 miles from the University 
Hospital 
5. Cognitive impairment- the inability to pass 
the  six-item screener or complete study 
instruments 
6. Have at least adequate health literacy  6. Inability to provide informed consent 
7. Symptomatic HF (NYHA I-IV)   
Abbreviations: HF: heart failure, NYHA: New York Heart Association, VAD: ventricular assist device 
Baseline data were collected approximately two weeks after hospital discharge. A 
research assistant (blinded to study group allocation) called participants to obtain socio-
demographic information and to administer the baseline Kansas City Cardiomyopathy 
Questionnaire (KCCQ) and Heart Failure Somatic Perception Scale (HFSPS). 
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Approximately 90 days after completion of the intervention, participants were called to 
complete the follow-up questionnaires (SCHFI, KCCQ, HFSPS). If the first follow-up 
call was unsuccessful, the research assistant would try every 3 to 5 days for up to 60 
days. If there was no contact with the participant after 60 days from the expected follow-
up date, the participant was considered lost to follow-up.  
Intervention Description 
 As described in detail elsewhere,28 participants assigned to the intervention group 
received a MI tailored intervention that included a home-based MI intervention and 3-4 
follow-up phone calls over the course of 90 days. Participants assigned to the usual care 
group continued with their usual care without further intervention. We chose this model 
of delivery for the intervention based on the Situation Specific Theory of Self-Care 
theoretical framework and our previous research.12 During the home visit the nurse 
worked with the participant using a MI approach to identify specific client-centered goals 
related to HF self-care. Together they developed a client-directed plan for accomplishing 
the goals, which were reinforced in the follow-up phone calls. A case study details how 
the nurse used the MI intervention to increase patient motivation and develop a plan for 
incorporating self-care behaviors into the daily routine of one participant.37 
Study Measures and Outcomes 
 
Self-care. Self-care was measured using the SCHFI v. 6.2, which is a 22-item, 
interviewer-administered instrument that quantifies self-care maintenance, self-care 
management, and self-care confidence (self-efficacy) for patients with HF.33,38 The 
SCHFI was written for a sixth grade reading level and takes approximately 5 to10 
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minutes to complete. Scores on each scale were standardized to range from 0 to 100—
higher scores indicate better self-care. A score of 70 or greater in each self-care scale 
score is considered adequate and an improvement of 8 points is considered a clinically 
significant improvement.33 Cronbach’s α is not recommended as a measure of reliability 
for these scales because both self-care maintenance and self-care management scales are 
multidimensional.39 Using more appropriate coefficients, for the self-care maintenance 
scale, the reliability coefficients ranged from 0.75 to 0.83, depending on which 
coefficient was used. For self-care management, reliability coefficients ranged from 0.66 
to 0.77. Self-care confidence is unidimensional and the various reliability coefficients, 
including Cronbach’s alpha, ranged from 0.84 to 0.90.39 In a recent exploratory factor 
analysis, the comparative fit index construct validity scores were: 0.92 for self-care 
maintenance; 0.95 for self-care management and 0.99 for self-care confidence.40 
Concurrent validity of the SCHFI v 6.2 has been demonstrated by comparing it to the 
European Health Failure Self-care Behavior Scale (r= -0.65, p<0.001).40  
Quality of life. Quality of life was measured with the KCCQ, which has 23 items 
that can be quantified into five subscales: physical limitations, symptoms, quality of life, 
social interference, and self-efficacy. Each domain-specific subscale and the overall 
clinical summary score range from 0 to 100 (higher scores indicate better outcomes).41 In 
another population of patients with heart failure the internal consistency of the KCCQ is 
reported as being high (Cronbach’s α 0.92).42 Tests of construct validity for the KCCQ 
have strong associations with NYHA class, SF-36 and the six minute-walk-test.41  
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Acute Physical Heart Failure Symptoms. Acute physical HF symptoms were 
measured with the HFSPS. This scale asks how much participants were bothered by 
common symptoms of HF during the previous week. The responses to the 18-items range 
from 0 (I did not have this symptom) to 5 (extremely bothersome).43 Scores were 
summed with higher values indicating worse physical symptom distress. The reported 
reliability of the HFSPS scale is 0.90.44 Validity was demonstrated when the two 
domains, dyspnea and early/non-specific congestion were associated with survival at 180 
and 365-days.45  
Participant characteristics. Age, gender, comorbid conditions, prescribed 
medications, diagnostic lab tests, and echocardiogram results were obtained from the 
medical record. During baseline interviews research assistants obtained information on 
race/ethnicity, insurance status, years of education, perceived and general health from the 
participant. General health was measured by rating their health now compared to a year 
ago. Responses ranged from 1 (much worse) to 5 (much better) compared to a year ago. 
Participants were also asked about the quality of their social support and responses 
included fair, satisfactory, good or very good.  
Traditional questions about income characteristics (sources, amounts received) 
have been wrought with a wide range of bias46 and random error in both government 
surveys and other types of research.47 So, income was measured with the question, 
“Financially, would you say you are: comfortable; have more than enough to make ends 
meet; have enough to make ends meet; or do not have enough to make ends meet?” 
Data Analysis 
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Standard descriptive statistics were used to describe all study covariates at 
baseline. Independent sample t-tests were conducted for continuous variables and chi-
squared tests for categorical variables. We assessed whether randomization achieved 
balance across study covariates between the two study groups for baseline demographic 
and clinical characteristics. We also measured whether there were any differences in 
participants who completed the study compared to those who were lost to follow-up 
(response bias). Gender specific analyses were completed to further explain differences 
between groups.  
We used t-tests to assess for change in self-care maintenance and self-care 
confidence, physical HF symptoms and quality of life between baseline and 90 days 
within and across groups. We used chi-squared tests for differences in proportions to 
assess for improvement in self-care management because only a subset of participants 
was symptomatic and able to respond to these questions. Data analyses were conducted 
using StataSE 13.1 (College Station, Texas). 
 For the primary outcome (self-care maintenance) a model comparison approach48 
was applied throughout the model building process starting with covariates associated in 
bi-variate analyses with the outcome variable (p<0.05); then a priori factors were added. 
Factors that were considered in the models but were not significant and did not contribute 
to the robustness of the model were removed. The final model for predictors of change in 
self-care maintenance included the following eight variables: intervention group, general 
health, sleep apnea, financial status, coronary artery disease, gender, support quality, and 
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having a home health nurse. These eight variables were adjusted in the main analyses of 
group differences over time. 
Results 
 
The CONSORT diagram (Figure 6.1) reflects participants who were screened, 
enrolled, randomized and included in the analyses for both self-reported and objective 
outcomes between the two groups. A total of 100 participants were enrolled and 67 
completed the study of self-reported outcomes. For these outcomes, including the 
primary outcome of self-care, the overall attrition rate was 33%, (13% in the usual care 
group and 42% in the intervention group) consistent with other studies of patients with 
HF.49 There were no statistically significant differences in the socio-demographic or 
clinical characteristics of participants who completed versus did not provide self-reported 
follow-up data. There were also no statistically significant differences in the self-care, 
physical HF symptom or quality of life at baseline between those who completed and did 
not complete the study. Thus, the missing at random assumption was not violated. 
Participants in the study had a mean age of 62 years and ranged in age from 23 to 
86 years (Table 6.2). This sample of adults was predominantly male (60%) and Black 
(>50%). This was a fairly low educated group with most having no more than a high 
school education. Many participants were unemployed or disabled, one-third reported 
financial distress, and three-quarters reported poor or fair health. Clinically, 30% had 
ischemic etiology and almost half had systolic HF with a reduced left ventricular ejection 
fraction (LVEF). Overall, participants in the study were functionally compromised 
(83.6% NYHA Class III or IV). Participants were also on numerous medications (12 SD 
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±5.5) and lived with multiple comorbidities (5.5, SD ± 2.8). In terms of support, most 
people lived with another person and reported having good or very good support. 
Figure 6.1 CONSORT diagram showing participant study flow 
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Table 6.2a. Baseline socio-demographic characteristics by randomization group 
 Randomization group (mean +/- SD or %) 
Variables Overall Total (N=67) 
Control 
Total (N=26) 
Intervention 
Total (N=41) 
p-value 
 
Age   62    (13.4)   63   (12.6) 60   (13.9)  0.397 
Gender     0.130 
  Female    20    (29.9)     5   (19.3) 15   (36.6)   
  Male   47    (70.2)   21   (80.8) 26   (63.4)  
Married/Partnered   31    (46.3)   15   (57.7) 16   (39.0)  0.135 
Race     0.128 
  Black   36    (53.7)   17   (65.4) 19   (46.3)  
  White   31    (46.3)     9   (34.6) 22   (53.7)  
Education     0.233 
  <High School   42    (62.7)   14   (53.9) 28   (68.3)    
  College/Grad School   25    (37.3)   12   (46.2) 13   (31.7)  
  Total years education   13      (2.3)   13     (2.2) 13     (2.4)  
Employment Status     0.834 
   Employed/Retired   32    (47.8)   12   (46.2) 20   (48.8)   
   Unemployed/Disabled   35    (52.2)   14   (53.9) 21   (51.2)   
Financial Status     0.435 
   Comfortable/Enough   45    (67.2)   16  (61.5) 29   (70.7)   
   Not enough   22    (32.8)   10   (38.5) 12   (29.3)   
Insurance Type     0.419 
   Government   50    (74.6)   18   (69.2) 32   (78.1)   
   Commercial/HMO   17    (25.4)     8   (30.8)   9   (22.0)   
Health Perception     0.088 
   Poor/Fair   49    (73.1)   16   (61.5) 33   (80.5)   
   Good/Very 
Good/Excellent   18    (26.9)   10   (38.5)   8   (19.5)   
Health in General     0.746 
   Worse/Same   37    (55.2)   15   (57.7) 22   (53.7)   
   Better/Much Better   30    (44.8)   11   (42.3) 19   (46.3)  
Home Health Nurse   49    (73.1)   18   (69.2) 31   (75.6)  0.566 
Provider Specialty     0.292 
   Medicine/Cardiology   16    (23.9)     8   (30.8)   8   (19.5)   
   HF Specialist   51    (76.1)   18   (69.2) 33   (80.5)  
Lives with another   51    (76.1)     21   (80.8)   30   (73.2)  0.477 
Support Quality     0.241 
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   Fair/Satisfactory   11    (16.4)      6    (23.1)     5   (12.2)   
   Good/Very Good   56    (83.6)     20   (76.9)   36   (87.8)   
Nurse Interventionist     0.902 
   Nurse 1   51    (76.1)     20    (76.9)   31   (75.6)   
   Nurse 2   16    (23.9)       6    (23.1)   10   (24.4)   
     
Table 6.2b. Baseline Clinical Factors by Randomization Group 
 Randomization group (mean +/- SD or %) 
Variables Overall Total (N=67) 
Control 
Total (N=26) 
Intervention 
Total (N=41) 
p-value 
 
NYHA Functional Class     0.125 
   Class I/II   11    (16.4)      2      (7.7)    9    (22.0)    
   Class III/IV   56    (83.6)    24    (92.3)   32   (78.1)  
HF Etiology     0.299 
   Ischemic    20    (29.9)     9   (34.6) 11   (26.8)  
   Non-ischemic   31    (46.3)     9   (34.6) 22   (53.7)  
   Other   16    (23.9)     8   (30.8)   8   (19.5)  
HF Type     0.478 
   Systolic   32    (47.8)   10   (38.5) 22   (53.7)  
   Diastolic   13    (19.4)     6   (23.1)   7   (17.1)  
   Mixed   22    (32.8)   10   (38.5) 12   (29.3)  
Ejection Fraction (%)   35    (16.8)   37   (16.5) 34   (17.2)  0.586 
Total comorbidities   5.5     (2.8)  5.4     (3.5) 5.6    (2.4)  0.689  
Pacemaker (any type)  21     (31.3)     8   (30.8) 13   (31.7)  0.936 
Medications (total)  12       (5.5)   12     (5.6) 12     (5.6)  0.782 
   Beta Blocker  57     (85.1)   24   (92.3) 33   (80.5)  0.186 
   Ace Inhibitor  33     (49.3)   11   (42.3) 22   (53.7)  0.365 
   ARB   7      (10.5)     4   (15.4)   3     (7.3)  0.293 
   Statin  40     (59.7)   16   (61.5) 24    (58.5)  0.807 
   Diuretic  59     (88.1)   23   (88.5) 36    (87.8)  0.936 
Baseline Lab Values     
   Sodium 135.7 (15.6) 137.6    (2.8) 134.5 (19.9)  0.434 
   Hemoglobin   11.6   (1.9)   11.8    (1.8)  11.4    (1.9)  0.370 
   Creatinine    1.7    (1.3)     2.0    (1.9)    1.5    (1.3)  0.139 
   BUN  34.8  (29.0)   30.5  (23.8)  37.6  (31.9)  0.338 
     
Abbreviations:HF: heart failure, NYHA: New York Heart Association, ARB: Angiotensin II Receptor  
Blockers, BUN:blood urea nitrogen, PE: Pulmonary Embolis, DVT: Deep vein thrombosis,  
CAD: coronary artery disease , COPD: chronic obstructive pulmonary disease, CV: cardiovascular disease 
 
 129 
Self-care Outcomes 
Overall, self-care maintenance (mean: 78.5, SD ±12.7) was adequate for the entire 
sample at 90 days (Table 6.3). Within the intervention group, there was significant 
improvement in self-care maintenance (p<0.01) over 90 days. Within the usual care 
group there was also significant improvement in self-care maintenance (p<0.01). 
However, absolute change in self-care maintenance was greater in the intervention group 
compared to usual care (12.1 vs 19.7 points, Cohen’s d= 0.44). Though the effect size 
was moderate, the difference between groups was not initially statistically significant. 
After adjusting for gender, general health, sleep apnea, financial status, coronary artery 
disease, support quality and having a home-care nurse, there was a statistically and 
clinically significant 8.9 point increase (95% CI: 1.0 -16.7) in the MI group compared to 
the usual care group (p=0.03) at 90 days. 
Overall, at baseline, 6.0% of the sample was asymptomatic and thus unable to 
complete the self-care management scale (3.9% in the usual care group and 7.3% in the 
intervention group; p=0.56). At follow-up, 32.8% of the sample was asymptomatic, but 
there was no difference between the groups in achieving asymptomatic status (p=0.44). In 
the intervention group 90% improved in self-care management and in the usual care 
group 73% improved in self-care management (p=0.07).  
In both groups self-care confidence improved more than 20 points (p<0.001) 
(Table 6.3). There were no statistically significant differences in improvement in self-
care confidence between the two study groups (p=0.31), although the absolute change in 
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self-care confidence was higher in the intervention compared to usual care group (26 vs 
21 points, Cohen’s d=0.26).  
Physical HF symptoms, clinical summary score and quality of life 
At baseline the mean score on the HFSPS, the measure of physical HF symptoms, 
was 19.9 (SD ± 19.4). At 90 days the mean HFSPS was 17.9 (SD ± 18.06) with no 
differences between (p=0.63) or within groups (MI: p=0.29; usual care: p=0.83). The 
mean score for men in the MI group decreased 7 points (95% CI: 0.58 to 13.50; p= 0.03) 
—indicating symptom improvement. There were no differences in the usual care group 
for men or for women in either group.  
The mean KCCQ clinical summary score at baseline was 56.1 ±24.6 (Table 3). 
The within group change over 90 days was significant (p=0.01) although the mean 
change of 10.3 points between baseline and follow-up was not different between the 
groups (p=0.67).  
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Table 6.3. Self-care at Baseline and 90-days follow-up for participants in the usual 
care or Motivational Interviewing Groups  
Variable Intervention 
mean (SD) 
Usual care, ,  
mean (SD) 
t-value (p) c 
Self-care maintenance    
     Baseline 59.9 (16.3) 64.7 (16.9) 1.2 (0.250) 
     90-days 79.6 (11.5) 76.8 (14.5) -0.9 (0.383) 
     Absolute change  19.7 (16.0) a 12.1 (18.3) a -1.8 (0.077) 
Self-care management    
     Baseline 50.1 (26.3) 56.7 (26.5) 1.0 (0.321) 
     90-days 48.4 (37.1) b 41.2 (38.1) -0.8 (0.442) 
     Absolute change  1.7 (39.9) 15.6 (48.0) -0.6 (0.564) 
Self-care confidence    
     Baseline 54.6 (22.2) 61.4 (18.5) 1.3 (0.204) 
     90-days 81.2 (18.0) 83.0 (16.3) 0.4 (0.690) 
     Absolute change  26.6 (20.8) a 21.6 (16.8) a -1.0 (0.309) 
KCCQ QOL    
     Baseline 50.81 (29.27) 60.25 (28.01) 1.3 (0.196) 
     90-days 61.59 (26.67) 65.06 (28.48) 0.5 (0.614) 
     Absolute change  10.77 (28.15) 4.81 (21.37) -0.9 (0.359) 
KCCQ CSS    
     Baseline 54.60 (24.49) 58.50 (25.12) 0.6 (0.531) 
     90-days 63.94 (24.82) 69.41 (23.89) 0.9 (0.382) 
     Absolute change  9.34 (23.91) 11.86 (20.86) 0.4 (0.665) 
HFSPS Total Score    
     Baseline 21.56 (19.23) 17.31 (19.65) -0.9 (0.385) 
     90-days 18.76 (17.28) 16.58 (19.52) -0.5 (0.634) 
     Absolute change  -2.81 (16.79) -0.73 (17.14) 0.5 (0.627) 
 
a: significant improvement (p<0.01) from baseline to 90-days by paired t-tests 
b: N=41= because the follow-up score was not recorded for people who were asymptomatic at 90 days 
(n=26) 
c  p-values are for differences between group t-tests 
 
The combined mean KCCQ quality of life score for all participants was 54.5 (SD ± 29.0) 
at baseline and 62.93 (SD ±27.2) at follow-up (Table 6.3). The absolute change in quality of life 
of 10.7 points from baseline to 90 days within the MI group was statistically significant (p=0.02) 
compared to the change of 4.8 points in the usual care group (p=0.26) but the difference in quality 
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of life between groups was not significantly different (p=0.36) at 90 days. In a specific gender 
analysis, men within the MI group had an improvement of 12 points ±31.46 (p=0.05) in 
quality of life, while there were no significant differences for men in the usual care group 
or for women in either group.  
Discussion 
 
The results of this randomized controlled trial designed to test the efficacy of a MI 
intervention shows that using a MI approach improved self-care maintenance in this 
sample of adults with HF. Further, there was evidence of a trend in improved self-care 
management. These results support our earlier conclusion that motivating people with HF 
to take more control over their health with self-care can help them achieve optimal health 
outcomes.50  
The finding that the MI intervention improved self-care maintenance is consistent 
with others who have used MI as a tool to improve physical activity in various patient 
populations living with chronic illness, including older adults with HF,51 chronic 
obstructive pulmonary disease (COPD),52 fibromyalgia53 and chronic pain.54,55 More 
specifically, MI is currently being tested to improve patient engagement and motivation 
for self-management in patients with COPD,52 as a management strategy to sustain the 
clinical benefits of exercise for fibromyalgia53 and to improve disability, pain intensity, 
(pain-specific) self-efficacy, motivation, and quality of life for people with chronic 
musculoskeletal pain.55 Tse and colleagues also reported improved change scores for 
quality of life, self-efficacy, physical and psychological function and compliance with 
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exercise in a group receiving MI with a physical exercise intervention compared to a 
usual care group.54  
In MITI-HF, quality of life improved in both study groups over 90 days; however, 
there were no statistically significant differences between groups. Brodie and colleagues 
also reported improvement in quality of life over 5 months after being in the MI physical 
activity intervention.13 One of the reasons for the differences between MITI-HF and the 
Brodie study may be due to the use of different quality of life measurement tools. They 
used the Medical Outcomes Short Form-36 Health Survey and the Minnesota Living with 
Heart Failure questionnaire while we used the KCCQ in MITI-HF. The Brodie study also 
had a longer follow-up period. In addition, physical activity is known to improve quality 
of life14 whereas in MITI-HF participants chose a variety of behavior changes, some of 
which are associated with a decrease in socialization options—including maintaining a 
low sodium diet—which may negatively impact quality of life. Beckie and colleagues 
also designed a study to promote healthy behavior change for women with coronary heart 
disease using MI and they reported improvement in global quality of life in the MI 
compared to usual care group.56,57 Differences in study results between MITI-HF and the 
Beckie randomized controlled trial may be due to the fact that the Beckie study was 
powered to detect changes in quality of life (the sample size was much larger (n=225)). In 
addition, the intervention was much longer (6-months), more intensive (three, 60-min in-
person MI sessions and 10 weeks of psychoeducational sessions) and gender-specific. 
The patient-population was also less sick than the MITI-HF sample of patients with HF. 
The quality of life measures in the two studies were also different. Beckie et al. used 
Multiple Discrepancies Theory and Self-Anchoring Striving Scale questionnaires to 
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measure quality of life compared to the KCCQ used in MITI-HF. It is also possible that 
in a functionally compromised population of patients with severe HF that there is a 
ceiling effect of how much quality of life can improve over time due to the impact of 
worsening of disease severity.  
In MITI-HF, the MI intervention did not improve participant’s self-care 
confidence (self-efficacy) over time compared with usual care. In contrast, there is early 
evidence from a study by Paradis and colleagues that reports improvement in self-
efficacy using an MI approach in patients with HF.58 In the Paradis study, patients 
received a similar dose of MI from a nurse (one face-to-face MI intervention followed up 
by two telephone conversations) and yet there was no improvement in self-care 
maintenance but there was improvement in self-care confidence over 1-month.  
Differences in study design between the two studies may explain the differences in self-
care outcomes, including length of patient follow-up (30 versus 90 days) and at least one 
or two more follow-up MI phone calls in MITI-HF by the nurse.  
MI has also been tested in other chronic disease patient populations to improve 
self-efficacy and clinical outcomes such as weight reduction in obese youth59 and 
physical activity in aging adults.60 In the Walpole study with obese youth, there were no 
statistically significant differences between the MI and social skills training groups for 
improvement in weight loss or self-efficacy; however, participants in both groups showed 
significant increases in self-efficacy and a trend of decreased body mass index z-scores.59 
Lilienthal and colleagues did a telephone-based MI intervention to increase physical 
activity and self-efficacy in aging adults.60 The MI group reported higher self-efficacy for 
  135 
physical activity at six months follow-up.60 Once again, differences in the study results 
between MITI-HF and the Lilienthal study may be due to differences in disease severity 
between patient populations (those in MITI-HF study were much more functionally and 
physically compromised) and a longer follow-up period in the Lilienthal study (90 days 
versus 6 months). 
Strengths/Limitations 
Strengths of this study include minority participation (over 50%), with women 
well represented. One limitation was that objective measures of self-care behaviors (e.g. 
pedometer for exercise) were not used in this study. The largest limitation was the loss of 
participants to follow-up and specifically the difference in attrition for the self-reported 
outcomes between the usual care and MI group. One of the proposed reasons for 
differential dropout was that the MI group had at least 60% more points of contact than 
the usual care group, thus increasing opportunities for dropout.  
Conclusions 
MI is a successful approach for improving self-care maintenance for patients with 
HF. Future studies should consider using a MI approach to improve self-care.  
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CH VII-SUMMARY AND CONCLUSIONS 
Introduction 
 
Patient outcomes related to heart failure (HF) continue to be poor, including high 
hospitalization rates, early death, exorbitant costs, intractable symptoms, and low quality 
of life (QOL).1-4 To improve patient outcomes, better management strategies that 
incorporate optimized medical therapy with effective self-care are critical.5-7 This body of 
work addressed several critical elements of HF self-care. The Situation Specific Theory 
of Heart Failure Self-Care was used to frame these studies.8 This theory conceptualizes 
HF self-care as having two core components, choosing positive routine health practices 
(‘self-care maintenance’) and making decisions around the management of signs and 
symptoms of HF when they occur (‘self-care management’).8,9  
The primary purpose of this body of work was to strengthen the evidence base for 
self-care by studying two understudied aspects of HF self-care maintenance—consuming 
a low-sodium diet and exercising. The secondary purpose was to test the efficacy of a 
tailored motivational interviewing (MI) approach to improve self-care, QOL, physical HF 
symptoms and clinical outcomes. The aims of these studies were to: 1) identify predictors 
of high sodium intake, 2) identify distinct biomarker patterns and predictors of worst 
biomarker patterns in response to exercise, and 3) test the efficacy of MI to improve HF 
self-care. This final chapter provides a summary and discussion of each study aim and 
concludes with recommendations for future research and implications for clinical 
practice.  
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Summary and Discussion of Principal Findings 
 
Predictors and patterns of high sodium excretion using multiple analytic methods 
The first aim was to identify predictors of high sodium consumption over time in 
patients with HF (Ch. II). The principal findings are summarized in Table 7.1. In brief, 
three factors were associated with excess sodium consumption, two of which, obesity and 
diabetes mellitus, are modifiable by changing dietary food patterns. The study reported in 
Ch. III is an extension of Ch II. Instead of setting a priori sodium levels based on Heart 
Failure Society of America (HFSA) guidelines,10 naturally-occurring patterns of sodium 
intake were driven by the study data. Two patterns of sodium consumption were 
identified using growth mixture modeling (GMM), one that was much higher than 
recommended (>4.4 g/day) and the other that was broadly adherent (2.4 g/day) with 
current Institute of Medicine (IOM) recommendations.11 In this study, the predictors of 
high sodium consumption were: 1) obesity, 2) diabetes mellitus and 3) younger age (< 65 
years). These two studies provide a framework for targeting specific HF populations with 
nutritional counseling and guidance.  
Table 7.1 Principal Findings: Specific Aim 1 
Specific Aim 1: Identifying predictors and patterns of high sodium intake using 
multiple analytic methods 
Studies  Principal Findings 
Identifying predictors of 
higher than recommended 
sodium intake in HF 
patients using a mixed 
effect logistic analysis of 
longitudinal data 
The adjusted odds of higher sodium excretion were 
higher for patients who were obese, had diabetes and 
for patients who were cognitively intact. 
 
Identifying subgroups of 
sodium adherence in adults 
with HF 
Two distinct patterns of sodium intake were identified 
in patients with HF using GMM. Being overweight 
and obese, less than 65 years of age or having diabetes 
mellitus were associated with a 4-fold incremental 
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increase in the likelihood of being in the higher than 
recommended pattern of urine sodium. 
 
In addition to taking medications as prescribed, dietary sodium restriction is the 
most common self-care behavior recommended for patients with HF.12-14 As such, these 
studies are an important contribution to the literature because they demonstrate that 
patients with HF are consuming higher sodium intake than recommended and that 
specific patient characteristics are associated with sodium consumption that is almost 
double the recommended intake. Excess sodium consumption may be exacerbating 
symptoms of HF and putting patients at higher risk for hospitalization and death.15  
The topic of sodium restriction has come under intense debate following 
conflicting reports about sodium restriction being either beneficial or harmful.16 Some 
observational studies report an association between a lower sodium diet and improved HF 
outcomes.15,17,18 Other studies report different results based on NYHA severity.18,19 
Lennie and colleagues were the first to report differential event risk by HF severity based 
on sodium intake.19 Patients with NYHA class III/IV were more likely to be 
rehospitalized if they consumed ≥ 3g/day of dietary sodium, and patients with NYHA I/II 
were more likely to be hospitalized if sodium intake was < 3 g/day.19 Similarly, Song and 
colleagues reported differential event-free survival for patients with mild compared to 
severe HF in response to three categories of sodium intake.20 They found that sodium 
restriction < 2 g/day was associated with higher event risk for patients with NYHA Class 
I/II and lower event risk for patients with NYHA Class III/IV.20 In another observational 
cohort study by Pfister and colleagues, they reported a U-shaped association between 
urine sodium excretion and risk of HF from the EPIC-Norfolk study.21  
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In contrast, the results of some RCTs indicate that dietary sodium restriction may 
actually cause harm.22-24 Paterna and colleagues enrolled 232 patients with HF (New 
York Heart Association (NYHA) class II-IV, 55-83 years of age, ejection fraction < 35% 
and serum creatinine < 2 mg/dl).23 Thirty-days after discharge, participants were 
randomized to a diet of either 1.8 or 2.8g of sodium per day. In addition, the study 
protocol included 250-500mg of furosemide twice daily and a 1-L fluid restriction. After 
180 days the 2.8g sodium diet was associated with reduced admissions and lower 
mortality and the 1.8g sodium diet was associated with worse renal function.23 These 
study results were repeated in a larger sample.24 Another study also suggested that severe 
sodium restriction is harmful in patients with reduced ejection fraction.22 Two limitations 
of these findings were that all studies came from the same group in a localized region in 
Italy and the results have not been replicated elsewhere. Due to the controversy between 
the observational and randomized studies, the Institute of Medicine (IOM) examined the 
evidence and now recommends a diet of no more than 2300 mg of sodium per day for all 
adult Americans, including those with comorbidities who were previously singled out as 
needing lower sodium thresholds (ie: diabetes mellitus and HF).11  
While controversy has waged about the lower threshold of sodium consumption, 
the reality is that most patients with HF consume far more than the maximum 
recommended amount. The mean urine sodium excretion for the entire sample reported in 
Chapters II & III ranged from 2770 mg/d (1750-3950 mg/d) at baseline to 2780 mg/d 
(1900-3790 mg/d) at six months.25 These values are consistent with other studies that 
report a mean consumption of 2671 mg/d26 and 3190 mg/d of sodium.27 The IOM’s cut-
off of no more than 2300 mg/d is lower than any of the means reported in these studies of 
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patients with HF. Given the context that the average adult American consumes 
approximately 3,400 mg of sodium per day28 and that most patients with HF consume 
more than the maximum recommended guidelines, the messaging to patients with HF 
should be consistent--it is still a priority to consume a low-sodium diet.  
Successfully advocating for sodium restriction will take a multi-faceted approach, 
including policy advocacy to reduce sodium in processed foods, consumer education and 
behavior change. Arcand and colleagues provide a good example of how to navigate the 
common lack of awareness about food sodium content in patients with HF by developing 
a Web-based sodium intake screening tool called the Salt Calculator, in which individuals 
can quantify their sodium intake.29 In the future, genomic studies may also be able to 
guide personalized sodium intake based on anthropomorphic measures.30 
The strengths of the studies reported in Chapters II and III are that they both used 
repeated measures of sodium excretion on the same individuals over a six-month period. 
The study reported in Ch II also used robust and transparent imputation methods to 
address potential bias from incomplete data. A limitation of the study reported in Ch II 
was the selection of a binary cut-point for adherence to dietary recommendations based 
on NYHA functional class scores published by the HFSA.10 In retrospect, this was an 
overly restrictive cut-point that allowed for simple associations, but did not allow more 
granular detail and analysis of sodium consumption patterns. One of the strengths of the 
study reported in Ch III was that due to the use of GMM, the patterns of sodium intake 
(or self-care maintenance) could vary naturalistically.   
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The primary limitation of the studies reported in Chapters II and III is the 
measurement of sodium intake using a 24-hour urine sodium collection. There have been 
doubts about the validity of 24-hour urine sodium collection for patients with HF on 
evidence-based pharmacotherapy, specifically diuretic medications, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers and aldosterone 
antagonists.31,32 In addition, 24-hour urine sodium collection is limited in that it only 
captures sodium intake over 24 hours rather than over a longer time frame. There are also 
limitations of self-reported sodium intake, including reports that it is not reliable among 
patients with HF.33 In general, following a low sodium diet is often interpreted by 
patients as not using salt for cooking, rather than reducing the consumption of high-
sodium canned, frozen or take-away food.33 Food diaries can also be subject to recall bias 
and the impact of social desirability.34 Overall, despite the limitations of a 24-hour urine 
sodium collection, it is still considered the gold standard for an objective measure of 
sodium intake even for patients with HF on diuretics.35  
While it is clear that very high sodium intake is not recommended for healthy 
adults or patients with HF, it is still not clear: (1) what the lowest and safest range of 
sodium intake is, (2) whether recommendations can be general or if they should be 
tailored to individuals or targeted to specific sub-groups, and (3) what the most reliable 
and valid approach is to measuring dietary sodium.30 Changes in policy should focus on 
reducing excess sodium across the food environment so that consumers have more choice 
in how much sodium is in their food,36 as well as raising consumer knowledge to identify 
and avoid high sodium foods.   
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Self-care maintenance: exercise and biomarkers 
 The second aim was to identify common and distinct patterns of change in serum 
biomarkers of inflammation and myocardial stress and quantify the influence of exercise 
therapy on patterns of change in a community-based sample of patients with HF. To 
address this aim, an analysis was conducted with data from the Heart Failure: A 
Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) RCT. The 
principal findings are detailed in Table 7.2.  
Table 7.2 Principal Findings: Specific Aim 2 
Specific Aim 2: The primary aim was to identify common and distinct patterns of change in 
serum biomarkers of high-sensitivity C-reactive protein (hsCRP) and N-terminal pro b-type 
natriuretic (NT-proBNP) and quantify the influence of exercise therapy on the patterns of change. 
Principal Findings 
1. Three statistically independent and clinically meaningful biomarker patterns of 
NTproBNP and hsCRP were identified and titled: “lowest and improving,” “elevated and 
stable,” and “elevated and worsening.” 
2. Participants randomized to the exercise intervention were 75% less likely to have the 
elevated/worsening pattern of NT-proBNP and hsCRP 
 
 The sample of patients with HF in this sample were relatively young (58 years), 
the majority were male (73%) with NYHA class II (71%). In this relatively high 
functioning sample of patients with HF enrolled in an RCT, three distinct biomarker 
patterns of inflammation and myocardial stress were identified. The most common 
pattern, “lowest/improving” (61% of the sample), was the most favorable pattern because 
it was characterized by the lowest levels of NT-proBNP and hsCRP at baseline and both 
biomarkers declined over 12-months. The second pattern was labeled “elevated/stable” 
(34% of the sample) and it was characterized by higher hsCRP and similar NT-proBNP 
to the lowest/improving pattern. The third pattern “elevated/worsening” was the smallest, 
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but most deleterious, (5% of the sample) characterized by the highest levels of NT-
proBNP and increasing hsCRP over 12-months.  
 Exercise was a protective factor for worse intermediary physiologic outcomes in 
patients with HF. Participants who were enrolled in the exercise intervention were much 
less likely (77%) to be in the elevated/worsening or elevated/stable pattern (47%). 
Overall, exercise therapy has been advocated for patients with HF to improve functional 
capacity37 and clinical outcomes.38 Moderate exercise is associated with a decreased risk 
of clinical events.39 The results of this study support the benefits of exercise therapy as 
being protective and contributing to slowing the progression of HF. Some of the 
mechanisms for the protective effect of exercise may be improving myocardial 
contractility, perfusion, endothelial dysfunction,40,41 angiogenesis,42 and coronary and 
peripheral skeletal vessel dilation.43  
 The reported protective effect of exercise is particularly relevant in the context of 
the recent decision by the Centers for Medicare & Medicaid Services to reimburse 
cardiac rehabilitation for patients with stable, chronic HF.44 Now that cardiac 
rehabilitation is reimbursable, there is a push for it to include broader self-care counseling 
to improve education and skills around medication compliance and monitoring/managing 
body weight.45 Because the benefits of exercise are limited by patient adherence, tailored 
approaches to engage patients are critical for any improvement or benefit from exercise. 
In addition, system-wide support should be put in place to get patients referred to cardiac 
rehabilitation.45 
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Motivational Interviewing Tailored Intervention for Heart Failure (MITI-HF) 
The third aim of this body of work was to integrate the previous two aims into a 
pilot RCT. Taking what was learned from Chapters II-IV we designed MITI-HF to test 
the comparative efficacy of a tailored MI intervention in improving HF self-care 
behaviors, physical HF symptoms, and QOL. The principal finding of MITI-HF was that 
the MI intervention improved the primary outcome of self-care maintenance over and 
above usual care even after controlling for demographic, clinical and health service 
factors (Table 7.3).  
Table 7.3 Principal Findings: Specific Aim 3 
Specific Aim 3: Implement and evaluate MITI-HF for its impacts on HF self-care over 90 days. 
Examine the impact of MITI-HF on secondary outcomes of physical HF symptoms and health 
related quality of life over 90 days.  
Principal Findings 
1. MI was a successful approach for improving self-care maintenance. Participants in the MI 
group had statistical and clinical improvements in self-care maintenance compared to the 
usual care group.  
2. There were no differences between the two study groups for self-care management, self-
care confidence, QOL or physical HF symptoms and response.  
 
The results of MITI-HF demonstrated that a tailored MI intervention improved 
self-care maintenance in a sample of adults with HF.  The study sample was 
predominantly Black; participants had multiple comorbid conditions and most were 
functionally compromised. At baseline the overall mean self-care maintenance score for 
this sample was adequate. At 90 days, there was significant improvement in self-care 
maintenance (p<0.01) in both groups; however, the absolute change was greater in the 
intervention compared to the control group. After adjusting for gender, general health, 
sleep apnea, financial status, coronary artery disease, support quality and having a home-
  149 
care nurse, there was a statistically and clinically significant 8.9 point46 increase in self-
care maintenance in the MI group compared to the usual care group. These results 
suggest that motivating people with HF to take more control over their health with self-
care can help them achieve optimal health outcomes.13  
A variety of educational approaches have been designed to improve self-care in 
patients with HF and results have been mixed.47-53 Albert and colleagues reported 
improved self-care management behaviors and higher self-care scores (over 3-months) in 
response to a video, which could be watched at home repeatedly over 3-months.50 In 
contrast, another intervention using remote patient education through a TV-channel found 
no differences in self-care behaviors over 288 days.51 Caldwell and colleagues tested a 
simplified education intervention in a small sample of rural patients and found that daily 
weighting was the only self-care behavior that improved over 3-months.52 Similarly, 
Baker and colleagues tested a telephone education/counseling versus single-education 
intervention and found that the “teach to goal” educational and behavioral support 
program provided benefit for self-care behaviors (irrespective of literacy levels).47 
Another study by Clark and colleagues also used an education support model and found 
that it improved several health status and self-care outcomes, including functional status, 
self-efficacy and self-care.49 Overall, there has been substantial heterogeneity in study 
results of educational interventions on self-care outcomes.  
Using skill-building rather than an educational approach, Dickson and colleagues 
found that a community-based tactical and situational HF self-care skill development 
delivered by lay health educators in community senior centers improved patients HF self-
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care and knowledge but not health-related QOL.54 The findings from the Dickson and 
colleague study are similar to MITI-HF, which reported improved self-care outcomes but 
not QOL at 90 days.  
MI has been used to improve self-care behaviors, including physical activity, in 
older adults with HF.55 Tse and colleagues have used MI to improve physical and 
psychological function and compliance with exercise.56 MI has also shown promise for 
improving self-care in other chronic diseases, including chronic obstructive pulmonary 
disease (COPD),57 fibromyalgia58 and chronic pain.56,59 MITI-HF built off a smaller pilot 
study results by Riegel and colleagues that found 71% of participants reported improved 
self-care in response to a MI intervention.60 Now MITI-HF is one of the larger studies to 
date to specifically use MI to improve self-care in patients with HF. Philosophically, MI 
is a promising approach to improve self-care because it is consistent with the underlying 
value of self-are that patients should be pro-actively involved in the maintenance and 
management of their own health and prevention of disease. 
Given the challenge of enrolling Blacks in RCTs,61 a major strength of MITI-HF 
is that it is generalizable to a population that has a high prevalence of HF62 and is under-
represented in HF research.63,64 In a mixed-methods study of 30 patients with HF, 
Dickson and colleagues described themes that self-care is highly influenced by cultural 
beliefs, such as HF being inevitable, attributed to stress and spirituality. Some self-care 
maintenance behaviors were well supported by cultural beliefs (medication adherence) 
whereas cultural preferences for specific foods were often not consistent with a low-
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sodium diet.65 Overall, there is a dearth of studies that test self-care interventions 
specifically among Blacks.  
One of the biggest challenges of MITI-HF was patient follow-up and assessment 
of self-care outcomes. At the baseline phone call (post-hospitalization), 52 participants 
were excluded from MITI-HF. Almost half were excluded because they were unable to 
be contacted post-hospitalization, despite having contact information for the participant 
and close relatives. Inability to contact participants was apparently due to lack of 
continuity of housing, changing geographic locations and shifting support structures that 
many of these patients face. In part due to this challenge of follow-up, there was a lack of 
statistical power to detect changes in the secondary outcomes.  
During the baseline phone call, 14% of patients were excluded prior to baseline 
data collection due to cognitive impairment. This was an unanticipated study limitation 
because severe cognitive impairment had been screened for using the 6-item screener66 in 
the hospital. Participants had passed the six-item screener and yet at baseline did not 
remember enrolling in the study. We characterized this as evidence of mild cognitive 
impairment and participants were screened out of the study prior to any data collection. 
In retrospect, the Montreal Cognitive Assessment (MoCA) would have been a better 
cognitive screening tool. It is more sensitive and specific to mild cognitive impairment 
and mild Alzheimer’s disease than the Mini-Mental State Exam (MMSE).67 According to 
the results of MITI-HF and other studies of patients with HF,68,69 good screening for 
cognitive impairment is important for the early identification of patients who may benefit 
from a tailored disease management program.  
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Cognitive impairment is highly prevalent among older patients hospitalized for 
HF; estimates range from 25-50% of patients.70 This is consistent with estimates that 15% 
of patients with HF have dementia and 24% have mild cognitive impairment.71 A recent 
systematic review reports that patients with mild cognitive impairment have problems 
performing self-care.68,72 Further research is needed on how cognitive impairment 
specifically affects the ability to sustain attention, concentration, memory capacity, motor 
speed and capacity to engage in executive functioning (problem solving and abstract 
reasoning). Future research is also needed on strategies for engaging patients with HF and 
cognitive impairment in better self-care because cognitive impairment has serious 
implications for self-care,73 including being a mediator for the effect of poor physical 
fitness on decreased functional independence in HF.74 
Another study limitation of MITI-HF was that objective measures of self-care 
outcomes were not included. Including a 6-minute walk test for physical activity and a 
food diary or 24-hour urine sodium excretion for adherence to a lower sodium diet would 
have strengthened the study. The primary outcome, self-care maintenance, was limited as 
a self-report process outcome. The next step for this research, is having a fully powered 
study to detect statistically significant differences between groups for clinical and health 
status outcomes. In this study, although patient-reported outcomes such as physical HF 
symptoms and QOL were measured, the study was not adequately powered to detect less 
than very large changes in these measures over time.  
Other study limitations include only two data collection points, limited follow-up 
timeframe (90 days) and differential attrition for self-care outcomes between the study 
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groups. More data collection points and a longer follow-up period would have allowed 
for non-linear assumptions of longitudinal data over time. At the same time, longer 
follow-up and more data points may have increased drop-out and missing data, which 
was already the largest limitation of the study.  
In a follow-up study to MITI-HF in Rome, Italy by Vellone and colleagues, an 
additional study group is being added to include only HF patient informal caregivers. 
According to a recent systematic review, informal caregivers play an important role for 
patients with HF, assisting patients with both concrete and interpersonal activities.75 
Results from a cross-sectional study indicate that having family member accompaniment 
to routine medical visits is associated with higher self-care maintenance and 
management.76 The impact of a patient-family partnership was tested in the Education 
and Support Interventions to Improve Self-Care [ENSPIRE] study. The intervention 
group of dyads received an intervention focused on dietary sodium intake and medical 
adherence by a master’s-prepared research nurse trained in the study protocol.27 Dietary 
sodium intake improved in the intervention groups compared to usual care, but 
medication adherence did not improve.27 Another study by Vellone and colleagues sought 
to describe the manner in which QOL and self-care vary within a couple dealing with 
chronic HF.77 Higher self-care maintenance (measured with the SCHFI 6.2) was 
associated with higher caregiver QOL.77 These results are consistent with MITI-HF, in 
which better support quality was one of the strongest predictors of improvement in self-
care maintenance (Beta Coefficient: 11.5, 95% CI: 1.3, 21.6, p= 0.028). While the 
involvement of caregivers, especially spousal caregivers, is ideal; some patients do not 
have that level of caregiving support. In a study with veterans receiving care at a Veteran 
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Affairs Medical Center, veterans reported that having an advocate—a member of the 
healthcare team, friends or family, helped them optimize their self-care management.78 
Given the challenge of cognitive impairment and the impact on caregivers, it is an 
important contribution to the literature that the MITI-HF follow-up study will include 
caregivers in the intervention and caregiver outcome data.  
Summary  
Overall, the results of this body of work are a significant contribution to the 
literature on HF self-care maintenance. There is now evidence that: 1) many patients with 
HF consume a high sodium diet; 2) modifiable predictors of consuming a high sodium 
diet include being obese or overweight and having diabetes; 3) non-modifiable predictors 
include younger age (< 65 years); 4) exercise was protective for being in the worst 
biomarker pattern of inflammation and myocardial stress; 5) a tailored MI intervention 
was feasible for patients with HF and improved patients’ self-care maintenance. This 
body of work answered a number of research questions using biomarker data and 
multiple methodologies. This work also combined existing secondary data analyses with 
the collection of primary data to further develop the evidence base for self-care 
maintenance.   
The results from the studies reported in this body of work indicate that many 
patients with HF experience a wide range of potential vulnerabilities (ie: financial, place 
of residence, health, age, functional status, developmental, ability to communicate 
effectively, race, ethnicity and gender) in addition to a lack of social and cognitive 
resources needed to successfully manage their health. Many patients also live with 
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multiple chronic illnesses. In the context of competing priorities, patients may need 
support to identify how to prioritize and make choices that optimize their health and 
wellness.  
The GMM analytic approach was a strength of the studies reported in both 
Chapters III & IV. The use of GMM in Ch IV allowed for the identification of previously 
unobserved biomarker patterns of change in an existing dataset of patients with HF. 
GMM holds future potential as an analytic tool for helping to explain heterogeneity in 
response to many self-care behaviors that are common among patients with HF. To date, 
the GMM methodology has been used by other researchers to identify patterns of self-
care management and changes in QOL,79  profiles of self-care management versus 
consulting behaviors,80 patterns of cognitive change in HF,81 and patterns of medication 
adherence.82 
 One of the challenges of using GMM is that relative to other statistical 
methodologies, it is relatively new (though it has been used for the past twenty years)83-85  
and it takes time for methodological innovation to reach mainstream acceptance. The 
feedback from a primarily clinical audience has been skepticism and concern about why 
multiple biomarkers would be analyzed simultaneously or why these methods were 
implemented instead of linear modeling. Just as there is a long lag between getting 
research findings into clinical practice,86 the same is true for methodological innovation.  
 Despite that limitation, there are multiple opportunities to use GMM in the future 
to identify specific archetypes or models of vulnerability in patients with HF. The first 
step will be a detailed systematic review and meta-analyses of existing literature to 
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statistically synthesize the effects of socio-demographic, environmental, clinical, 
symptom and behavioral factors on poor HF outcomes, and generate robust theoretico-
empirical archetypes of vulnerability.87 Archetypes of vulnerability can be characterized 
in a multicenter bio-behavioral research database containing socio-demographic, 
environmental, clinical, symptom, behavioral, QOL and clinical outcomes and tested in a 
large national dataset. 
Recommendations for Future Research 
 
 The focus of this research is consistent with the mission of the National Institute 
of Nursing Research (NINR), which is to support research on the science of health, 
focused on the promotion of health and improving quality of life by managing symptoms 
and enhancing innovation in science and practice. NINR is focused on supporting 
research that: 1) develops informatics-based solutions to promote health; 2) develops and 
creatively applies new and existing knowledge to the implementation of health 
information technology, including electronic health records; 3) expands knowledge and 
application of health care technologies to facilitate decision support, self-management, 
and access to health care.88  
Further development of informatics-based solutions to promote self-care in 
vulnerable populations, especially those with cognitive impairment, multiple chronic co-
morbidities and other vulnerabilities is critical. This issue was highlighted in MITI-HF, 
where patient follow-up was a major challenge, primarily for people with cognitive 
impairment. Being able to collect data with a simple mobile health application (app) 89,90 
may have helped to decrease study attrition. Sending text-reminders or simple email 
  157 
prompts instead of calling someone on the telephone may have reduced that barrier to 
engagement.  
There is also scope for improving remote monitoring systems and being able to 
more efficiently follow-up with vulnerable patients and improve patient-oriented 
outcomes. The effectiveness of telemonitoring to improve clinical outcomes (readmission 
for any reason or death from any cause within 180 days) for patients with HF was refuted 
in a large trial reported by Chaudhry and colleagues;91 however, remote monitoring has 
successfully been used to engage patients with HF in more intense self-care.92 
Evangelista and colleagues found that after 3-months, patients who had transmitted their 
weight and blood pressure through the remote monitoring system had improved 
activation, self-care, and QOL.92 
Likewise, in an effort to build better preventative services for Canadian patients 
with HF, Nolan and colleagues are testing a Canadian e-platform to provide counseling to 
facilitate adherence to self-care among patients with HF (ClinicalTrials.gov 
NCT01864369).93 In vulnerable populations with multiple competing chronic illnesses, 
the use of technology for follow-up monitoring and prompts is one avenue to promote 
and advance research.  
In future studies, I hope to utilize mobile apps for collecting data and smart 
phones with biological sensors to capture real-time data from vulnerable patients with HF 
who are also living with multiple chronic illnesses including cognitive impairment. 
Despite broad access to smart phone technology, there is still a digital divide by age and 
income.94 Overall, 58% of adult Americans have a smart phone and the prevalence is 
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highest among African-Americans (59%) and Hispanics (61%). People over 65 years 
have less access to a smart phone (19%) compared to 83% of people ages 18-29 years. 
There are also discrepancies by income, 47% for people earning < $30,000/yr and 81% 
for people earning >$75,000/yr.95 Future clinical research should harness the widespread 
use of smart phone technology for patient follow-up and address the limitations of health 
and technological literacy.  
To stay at the cutting edge, I believe that it is imperative to develop interventions 
that are responsive to patients needs in real-time. Future collaboration with computer 
science and bio-engineers to develop sensors that can monitor hemodynamic congestion, 
fatigue and dyspnea is critical. In addition, using electronic patient records for follow-up 
on patient bio-markers and pairing follow-up data collection with clinical follow-up 
appointments will make it more convenient for patients and less time-intensive for 
research assistants. Collaboration with health economists for cost-effectiveness analyses 
of interventions is also critical. For instance, the cost-effectiveness of a specific mobile 
application designed to promote cardiac self-care among patients with heart disease in 
Leon and Castille, Spain has been conducted and estimated to reduce costs and treatment 
of cardiac diseases by one-third.96 
Future research is needed on the decision making process and how to use tools to 
measure successful decision-making and outcomes to either reinforce or provide 
feedback for better decision-making. In the next era of genetics based personalized 
medication regimes, there is also scope for personalized bio-behavioral interventions 
because responses to interventions are often as disparate as responses to medications.  
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Recommendations for Clinical Practice 
 
 Many clinicians believe that patients with HF who take care of themselves will 
have better clinical and patient-oriented outcomes. While educating and promoting self-
care is assumed to be part of discharge teaching and disease management programs,97 it is 
usually rushed and abbreviated compared to what patients need. Health providers seldom 
have the time to adequately evaluate a patient’s self-care skills and barriers to 
improvement. Results from this body of work support fostering self-care practices using 
the principals of MI, particularly in the home where self-care practices can be 
contextualized to the patient’s natural environment.  
 In addition, this body of work supports the use of targeting more vulnerable 
groups of patients with nutritional support and counseling. For instance, younger patients, 
those who are obese and have diabetes mellitus are high risk for consuming sodium levels 
that are almost double the recommended values. Clinicians can use these data to support 
more targeted interventions for patients with these clinical characteristics in order to 
ensure that the patients understand the risks of high sodium consumption and how to 
quantify how much sodium they are consuming.  
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